[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fXJiDzmEANwB4EcIQRBo1HgSh7rgBOmmlIFDNrvq-kUA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"The University of Texas Health Science Center at San Antonio",[4],426,false,89,13,53892,61,221,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Type 2 Diabetes",18,{"name":18,"count":19},"Breast Cancer",15,{"name":21,"count":22},"Schizophrenia",12,{"name":24,"count":22},"Aging",{"name":26,"count":27},"Prostate Cancer",11,{"name":29,"count":27},"Bipolar Disorder",{"name":31,"count":32},"Diabetes Mellitus, Type 2",9,{"name":34,"count":35},"Unspecified Adult Solid Tumor, Protocol Specific",8,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04081220","Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2","2023-12-20","IMG-7289",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02891538","Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients","2024-12-02","Epigallocatechin gallate",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04629495","Rapamycin - Effects on Alzheimer's and Cognitive Health","2026-03","Rapamycin",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06977711","Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","2026-04-15","Loncastuximab",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05696691","Ketamine & Crisis Response Plan for Suicidal Ideation in the ED","2026-04-30","Ketamine Hydrochloride",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05282706","Use of Aromatherapy in Conjunction With Physical\u002FOccupational Therapy in an Acute Care Setting","2026-05","Lavender Oil",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05705414","Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis","2026-06","Valine",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT03765567","Placement of Antibiotic Powder in Wounds During the Emergency Room","2026-07","Vancomycin",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06108076","Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes","2026-07-31","Ketone Monoester",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT02823665","The Effects of Bariatric Surgeries on Glucose Metabolism","2026-08","Exendin-",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,230,271,289,310,336,369,399,421,447,465,483,566,602,636,662,688,710,728,754,772,798,816,840,858,932,1006,1044,1073,1097,1115,1133,1159,1177,1195,1213,1238,1256,1274,1292,1310,1328,1346,1364,1382,1408,1453,1475,1506,1528,1560,1578,1603,1622,1644,1662,1680,1713,1803,1825,1857,1884,1917,1955,1990,2014,2039,2057,2075,2099,2124,2142,2166,2184,2202,2220,2244,2262,2287,2312,2336,2361,2385,2403,2421,2448,2472,2494,2516,2534,2559,2585,2610,2633,2658,2683,2730,2779,2812,2846,2872,2908,2930,2952,2980,3002,3033,3072,3107,3129,3151,3175,3193,3217,3235,3258,3283,3301,3319,3343,3361,3385,3411,3429,3447,3465,3483,3507,3531,3549,3572,3590,3613,3631,3649,3675,3693,3717,3735,3764,3782,3800,3818,3836,3854,3872,3897,3922,3940,3958,3983,4001,4027,4049,4073,4097,4125,4143,4161,4179,4202,4220,4238,4260,4287,4311,4333,4357,4379,4404,4422,4444,4468,4492,4514,4535,4557,4581,4599,4617,4640,4658,4680,4710,4745,4767,4790,4815,4833,4857,4880,4898,4916,4934,4958,4982,5005,5030,5048,5072,5094,5121,5145,5170,5194,5218,5246,5264,5282,5308,5326,5352,5377,5401,5426,5447,5472,5490,5517,5548,5575,5593,5619,5637,5659,5683,5707,5725,5749,5767,5790,5816,5841,5859,5883,5905,5928,5954,5972,5993,6017],{"intervention":96,"totalTrials":97,"cells":98},"Pioglitazone",10,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":135,"NA":213},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":134,"soonestReadout":124},[108,119],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT00220961","Actos Now for Prevention of Diabetes (ACT NOW)","COMPLETED",[91],"2010-04","2004-01",602,[117,15],"Impaired Glucose Tolerance",[96],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT06246799","Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","RECRUITING",[91],"2029-04-30","2029-06-30","2024-11-07",256,[129],"Type 2 Diabetes (Adult Onset)",[131,96,132,133],"Tirzepatide","Sitagliptin","Metformin HCI XR",1,{"trials":136,"activeCount":212,"soonestReadout":206},[137,148,160,168,179,190,202],{"nctId":138,"briefTitle":139,"status":111,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"NCT01588470","Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)",[92],"2011-12","2006-06",130,[15,145],"Coronary Heart Disease",[147],"pioglitazone",{"nctId":149,"briefTitle":150,"status":111,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT00845182","Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function",[92],"2010-07","2007-06",43,[15,156,117],"Healthy",[96,158,159],"Exenatide","Pioglitazone and Exenatide",{"nctId":161,"briefTitle":162,"status":111,"phases":163,"primaryCompletion":141,"completion":141,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT01223196","Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes",[92],"2009-08",60,[15],[96],{"nctId":169,"briefTitle":170,"status":111,"phases":171,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT00227110","Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)",[92],"2005-11","2006-01","2002-10",55,[177],"Nonalcoholic Steatohepatitis",[96],{"nctId":180,"briefTitle":181,"status":111,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT00816218","Molecular Mechanisms of Type 2 Diabetes Mellitus",[92],"2006-07","2008-11","2003-03",39,[188],"Type 2 Diabetes Mellitus",[96],{"nctId":191,"briefTitle":192,"status":122,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":201},"NCT05838287","Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants",[92],"2029-08","2030-01","2023-07-10",78,[199,200],"Type 2 Diabetes Mellitus in Obese","Heart Failure With Preserved Ejection Fraction",[96],{"nctId":203,"briefTitle":204,"status":122,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":165,"conditions":208,"interventions":211},"NCT05305287","Quantifying Hepatic Mitochondrial Fluxes in Humans",[92],"2027-03-31","2022-11-01",[209,15,210],"Non-Alcoholic Fatty Liver Disease","Mitochondrial Metabolism Disorders",[96],2,{"trials":214,"activeCount":134,"soonestReadout":219},[215],{"nctId":216,"briefTitle":217,"status":122,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":226},"NCT02969798","Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)",[93],"2026-12","2027-07","2014-01-01",700,[31,224,225],"Impaired Glucose Tolerance (IGT)","Impaired Fasting Glucose (IFG)",[227,228,96,229],"Dapagliflozin","Saxagliptin","Metformin",{"intervention":231,"totalTrials":212,"cells":232},"Quetiapine",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":269},{"trials":234,"activeCount":101},[],{"trials":236,"activeCount":101},[],{"trials":238,"activeCount":101},[],{"trials":240,"activeCount":101},[],{"trials":242,"activeCount":134,"soonestReadout":85},[243,257],{"nctId":244,"briefTitle":245,"status":111,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":253},"NCT01588457","Sequential Multiple Assignment Treatment for Bipolar Disorder",[92],"2016-12","2011-06",112,[251,252],"Bipolar I Disorder","Bipolar II Disorder",[254,255,256,231],"Lithium","Divalproex","Lamotrigine",{"nctId":258,"briefTitle":259,"status":122,"phases":260,"primaryCompletion":85,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":267},"NCT05590637","Comparing Antipsychotic Medications in LBD Over Time",[92],"2027-02","2022-04-22",94,[265,266],"Parkinson's Disease Psychosis","Dementia With Lewy Bodies",[268,231],"Pimavanserin",{"trials":270,"activeCount":101},[],{"intervention":268,"totalTrials":134,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":287},{"trials":274,"activeCount":101},[],{"trials":276,"activeCount":101},[],{"trials":278,"activeCount":101},[],{"trials":280,"activeCount":101},[],{"trials":282,"activeCount":134,"soonestReadout":85},[283],{"nctId":258,"briefTitle":259,"status":122,"phases":284,"primaryCompletion":85,"completion":261,"start":262,"enrollment":263,"conditions":285,"interventions":286},[92],[265,266],[268,231],{"trials":288,"activeCount":101},[],{"intervention":76,"totalTrials":134,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":308},{"trials":292,"activeCount":101},[],{"trials":294,"activeCount":101},[],{"trials":296,"activeCount":101},[],{"trials":298,"activeCount":101},[],{"trials":300,"activeCount":134,"soonestReadout":75},[301],{"nctId":73,"briefTitle":74,"status":122,"phases":302,"primaryCompletion":75,"completion":220,"start":303,"enrollment":304,"conditions":305,"interventions":307},[92],"2020-10-05",200,[306],"Open Fracture",[76],{"trials":309,"activeCount":101},[],{"intervention":311,"totalTrials":134,"cells":312},"Pioglitazone 45 mg",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":334},{"trials":314,"activeCount":101},[],{"trials":316,"activeCount":101},[],{"trials":318,"activeCount":101},[],{"trials":320,"activeCount":101},[],{"trials":322,"activeCount":134,"soonestReadout":327},[323],{"nctId":324,"briefTitle":325,"status":122,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT03878459","Dapagliflozin Plus Pioglitazone in T1DM",[92],"2027-06","2027-12","2019-08-08",120,[332],"Type 1 Diabetes Mellitus",[311],{"trials":335,"activeCount":101},[],{"intervention":131,"totalTrials":212,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":359,"PHASE4":365,"NA":367},{"trials":339,"activeCount":101},[],{"trials":341,"activeCount":101},[],{"trials":343,"activeCount":134,"soonestReadout":348},[344],{"nctId":345,"briefTitle":346,"status":122,"phases":347,"primaryCompletion":348,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":358},"NCT06811324","Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults",[90],"2027-04-01","2027-06-01","2026-04-01",20,[353,354,355,356,357],"Obesity Prevention","Sarcopenia in Elderly","Cardiovascular Function","GLP - 1","Weight Loss",[131],{"trials":360,"activeCount":134,"soonestReadout":124},[361],{"nctId":120,"briefTitle":121,"status":122,"phases":362,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":363,"interventions":364},[91],[129],[131,96,132,133],{"trials":366,"activeCount":101},[],{"trials":368,"activeCount":101},[],{"intervention":132,"totalTrials":212,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":383,"NA":397},{"trials":372,"activeCount":101},[],{"trials":374,"activeCount":101},[],{"trials":376,"activeCount":101},[],{"trials":378,"activeCount":134,"soonestReadout":124},[379],{"nctId":120,"briefTitle":121,"status":122,"phases":380,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":381,"interventions":382},[91],[129],[131,96,132,133],{"trials":384,"activeCount":101},[385],{"nctId":386,"briefTitle":387,"status":111,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT00820573","Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM",[92],"2012-06","2012-10","2009-10",16,[394],"Diabetes",[132,229,396],"Sitagliptin + Metformin",{"trials":398,"activeCount":101},[],{"intervention":61,"totalTrials":134,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":417,"NA":419},{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":101},[],{"trials":406,"activeCount":101},[],{"trials":408,"activeCount":134,"soonestReadout":60},[409],{"nctId":58,"briefTitle":59,"status":122,"phases":410,"primaryCompletion":60,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":416},[90,91],"2026-12-31","2023-01-06",24,[415],"Suicide",[61],{"trials":418,"activeCount":101},[],{"trials":420,"activeCount":101},[],{"intervention":422,"totalTrials":134,"cells":423},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":443,"NA":445},{"trials":425,"activeCount":101},[],{"trials":427,"activeCount":101},[],{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":134,"soonestReadout":349},[432],{"nctId":433,"briefTitle":434,"status":435,"phases":436,"primaryCompletion":349,"completion":437,"start":438,"enrollment":413,"conditions":439,"interventions":441},"NCT07056699","SGLT2i, Pioglitazone, and Ketone Production in T1D","NOT_YET_RECRUITING",[91],"2027-06-30","2026-07-01",[440],"Type1diabetes",[422,442],"Pioglitazone 15 MG and 30mg",{"trials":444,"activeCount":101},[],{"trials":446,"activeCount":101},[],{"intervention":442,"totalTrials":134,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":461,"NA":463},{"trials":450,"activeCount":101},[],{"trials":452,"activeCount":101},[],{"trials":454,"activeCount":101},[],{"trials":456,"activeCount":134,"soonestReadout":349},[457],{"nctId":433,"briefTitle":434,"status":435,"phases":458,"primaryCompletion":349,"completion":437,"start":438,"enrollment":413,"conditions":459,"interventions":460},[91],[440],[422,442],{"trials":462,"activeCount":101},[],{"trials":464,"activeCount":101},[],{"intervention":133,"totalTrials":134,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":479,"NA":481},{"trials":468,"activeCount":101},[],{"trials":470,"activeCount":101},[],{"trials":472,"activeCount":101},[],{"trials":474,"activeCount":134,"soonestReadout":124},[475],{"nctId":120,"briefTitle":121,"status":122,"phases":476,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":477,"interventions":478},[91],[129],[131,96,132,133],{"trials":480,"activeCount":101},[],{"trials":482,"activeCount":101},[],{"intervention":51,"totalTrials":484,"cells":485},7,{"EARLY_PHASE1":486,"PHASE1":508,"PHASE2":510,"PHASE3":551,"PHASE4":562,"NA":564},{"trials":487,"activeCount":134,"soonestReadout":502},[488,498],{"nctId":489,"briefTitle":490,"status":111,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT01827618","Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy",[88],"2014-04","2012-04",29,[496],"Invasive Bladder Cancer Stage II",[51],{"nctId":499,"briefTitle":500,"status":122,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":506},"NCT06658093","RESTOR: PK\u002FPD mTORi Inhibition in Older Adults",[88],"2028-07","2026-03-04",194,[24],[51,507],"Everolimus",{"trials":509,"activeCount":101},[],{"trials":511,"activeCount":134,"soonestReadout":50},[512,521,530,538],{"nctId":513,"briefTitle":514,"status":111,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":520},"NCT02874924","Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly",[90],"2018-09","2016-06",34,[24],[51,51],{"nctId":522,"briefTitle":523,"status":111,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":351,"conditions":527,"interventions":528},"NCT04742777","Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]",[90],"2025-09-09","2022-02-01",[24],[529],"rapamycin",{"nctId":48,"briefTitle":49,"status":122,"phases":531,"primaryCompletion":50,"completion":50,"start":532,"enrollment":533,"conditions":534,"interventions":537},[90],"2021-08-11",40,[535,536],"Mild Cognitive Impairment","Alzheimer Disease",[51],{"nctId":539,"briefTitle":540,"status":541,"phases":542,"primaryCompletion":543,"completion":544,"start":545,"enrollment":101,"conditions":546,"interventions":550},"NCT04482712","Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS","WITHDRAWN",[89,90],"2022-01","2023-01","2021-04",[547,548,549],"Acute Lung Injury\u002FAcute Respiratory Distress Syndrome (ARDS)","Respiratory Failure","Sars-CoV2",[51],{"trials":552,"activeCount":101},[553],{"nctId":554,"briefTitle":555,"status":541,"phases":556,"primaryCompletion":526,"completion":557,"start":558,"enrollment":101,"conditions":559,"interventions":561},"NCT03298958","Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer",[91],"2022-05-01","2018-11-01",[560],"Bladder Cancer",[51],{"trials":563,"activeCount":101},[],{"trials":565,"activeCount":101},[],{"intervention":567,"totalTrials":212,"cells":568},"Sacituzumab Govitecan",{"EARLY_PHASE1":569,"PHASE1":582,"PHASE2":584,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":570,"activeCount":101},[571],{"nctId":572,"briefTitle":573,"status":111,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":581},"NCT03995706","Neuro\u002FSacituzumab Govitecan\u002FBreast Brain Metastasis\u002FGlioblastoma\u002FPh 0",[88],"2022-06-03","2024-03-20","2019-07-17",26,[580],"Glioblastoma",[567],{"trials":583,"activeCount":101},[],{"trials":585,"activeCount":134,"soonestReadout":261},[586],{"nctId":587,"briefTitle":588,"status":122,"phases":589,"primaryCompletion":261,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":595},"NCT04559230","Sacituzumab Govitecan in Recurrent Glioblastoma",[90],"2028-02","2022-01-06",32,[594],"Recurrent Glioblastoma",[567],{"trials":597,"activeCount":101},[],{"trials":599,"activeCount":101},[],{"trials":601,"activeCount":101},[],{"intervention":603,"totalTrials":212,"cells":604},"Ropivacaine",{"EARLY_PHASE1":605,"PHASE1":616,"PHASE2":618,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":606,"activeCount":101},[607],{"nctId":608,"briefTitle":609,"status":111,"phases":610,"primaryCompletion":611,"completion":612,"start":303,"enrollment":22,"conditions":613,"interventions":615},"NCT04302181","Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD",[88],"2021-07-01","2021-12-03",[614],"Stress Disorders, Post-Traumatic",[603],{"trials":617,"activeCount":101},[],{"trials":619,"activeCount":134,"soonestReadout":206},[620],{"nctId":621,"briefTitle":622,"status":122,"phases":623,"primaryCompletion":206,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":628},"NCT05889741","Combining Stellate Ganglion Block With Prolonged Exposure for PTSD",[90],"2027-08-31","2024-02-26",140,[614],[603,629],"Normal saline",{"trials":631,"activeCount":101},[],{"trials":633,"activeCount":101},[],{"trials":635,"activeCount":101},[],{"intervention":637,"totalTrials":134,"cells":638},"Dupilumab",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":640,"activeCount":101},[],{"trials":642,"activeCount":101},[],{"trials":644,"activeCount":134,"soonestReadout":649},[645],{"nctId":646,"briefTitle":647,"status":122,"phases":648,"primaryCompletion":649,"completion":650,"start":651,"enrollment":652,"conditions":653,"interventions":655},"NCT05720325","Dupilumab Effects Against Aeroallergen Challenge",[90],"2026-11","2027-11","2023-03-29",88,[654],"Asthma, Allergic",[637],{"trials":657,"activeCount":101},[],{"trials":659,"activeCount":101},[],{"trials":661,"activeCount":101},[],{"intervention":663,"totalTrials":134,"cells":664},"Bupropion Hydrochloride 150 MG",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":666,"activeCount":101},[],{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":134,"soonestReadout":675},[671],{"nctId":672,"briefTitle":673,"status":435,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":392,"conditions":678,"interventions":681},"NCT06609343","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis",[89,90],"2026-11-30","2027-01-30","2026-06-01",[679,680],"End Stage Renal Disease","Fatigue",[663],{"trials":683,"activeCount":101},[],{"trials":685,"activeCount":101},[],{"trials":687,"activeCount":101},[],{"intervention":41,"totalTrials":134,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":691,"activeCount":101},[],{"trials":693,"activeCount":101},[],{"trials":695,"activeCount":134,"soonestReadout":40},[696],{"nctId":38,"briefTitle":39,"status":697,"phases":698,"primaryCompletion":40,"completion":699,"start":700,"enrollment":32,"conditions":701,"interventions":703},"ACTIVE_NOT_RECRUITING",[90],"2026-12-20","2020-04-09",[702],"Thrombocythemia, Essential",[41],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":101},[],{"trials":709,"activeCount":101},[],{"intervention":629,"totalTrials":134,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":713,"activeCount":101},[],{"trials":715,"activeCount":101},[],{"trials":717,"activeCount":134,"soonestReadout":206},[718],{"nctId":621,"briefTitle":622,"status":122,"phases":719,"primaryCompletion":206,"completion":624,"start":625,"enrollment":626,"conditions":720,"interventions":721},[90],[614],[603,629],{"trials":723,"activeCount":101},[],{"trials":725,"activeCount":101},[],{"trials":727,"activeCount":101},[],{"intervention":729,"totalTrials":134,"cells":730},"Memantine",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":732,"activeCount":101},[],{"trials":734,"activeCount":101},[],{"trials":736,"activeCount":134,"soonestReadout":741},[737],{"nctId":738,"briefTitle":739,"status":435,"phases":740,"primaryCompletion":741,"completion":742,"start":50,"enrollment":743,"conditions":744,"interventions":746},"NCT07470606","Memantine +\u002F- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain",[90],"2030-03","2031-03",108,[745],"Brain Tumor",[729,747],"Raloxifene",{"trials":749,"activeCount":101},[],{"trials":751,"activeCount":101},[],{"trials":753,"activeCount":101},[],{"intervention":747,"totalTrials":134,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":134,"soonestReadout":741},[762],{"nctId":738,"briefTitle":739,"status":435,"phases":763,"primaryCompletion":741,"completion":742,"start":50,"enrollment":743,"conditions":764,"interventions":765},[90],[745],[729,747],{"trials":767,"activeCount":101},[],{"trials":769,"activeCount":101},[],{"trials":771,"activeCount":101},[],{"intervention":773,"totalTrials":134,"cells":774},"Tremelimumab",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":792,"PHASE4":794,"NA":796},{"trials":776,"activeCount":101},[],{"trials":778,"activeCount":101},[],{"trials":780,"activeCount":134,"soonestReadout":785},[781],{"nctId":782,"briefTitle":783,"status":122,"phases":784,"primaryCompletion":785,"completion":786,"start":45,"enrollment":592,"conditions":787,"interventions":790},"NCT06526104","Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis",[90],"2027-10-01","2027-12-01",[788,789],"Hepatocellular Carcinoma","Cirrhosis, Liver",[773,791],"Durvalumab",{"trials":793,"activeCount":101},[],{"trials":795,"activeCount":101},[],{"trials":797,"activeCount":101},[],{"intervention":791,"totalTrials":134,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":801,"activeCount":101},[],{"trials":803,"activeCount":101},[],{"trials":805,"activeCount":134,"soonestReadout":785},[806],{"nctId":782,"briefTitle":783,"status":122,"phases":807,"primaryCompletion":785,"completion":786,"start":45,"enrollment":592,"conditions":808,"interventions":809},[90],[788,789],[773,791],{"trials":811,"activeCount":101},[],{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":101},[],{"intervention":817,"totalTrials":134,"cells":818},"Lomustine",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":820,"activeCount":101},[],{"trials":822,"activeCount":101},[],{"trials":824,"activeCount":134,"soonestReadout":85},[825],{"nctId":826,"briefTitle":827,"status":122,"phases":828,"primaryCompletion":85,"completion":649,"start":829,"enrollment":830,"conditions":831,"interventions":832},"NCT04863950","Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma",[90],"2022-05-25",25,[580],[817,833],"Imipramine Hydrochloride",{"trials":835,"activeCount":101},[],{"trials":837,"activeCount":101},[],{"trials":839,"activeCount":101},[],{"intervention":833,"totalTrials":134,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":843,"activeCount":101},[],{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":134,"soonestReadout":85},[848],{"nctId":826,"briefTitle":827,"status":122,"phases":849,"primaryCompletion":85,"completion":649,"start":829,"enrollment":830,"conditions":850,"interventions":851},[90],[580],[817,833],{"trials":853,"activeCount":101},[],{"trials":855,"activeCount":101},[],{"trials":857,"activeCount":101},[],{"intervention":859,"totalTrials":860,"cells":861},"Empagliflozin 25 MG",6,{"EARLY_PHASE1":862,"PHASE1":896,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":930},{"trials":863,"activeCount":895,"soonestReadout":868},[864,878,887],{"nctId":865,"briefTitle":866,"status":122,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":875},"NCT06229678","Ketones, SGLT2, HFrEF",[88],"2026-11-01","2027-03-01","2024-01-25",71,[873,874],"Type2diabetes","Heart Failure With Reduced Ejection Fraction",[876,877],"Empagliflozin 25 MG Oral","Acipimox 250 Mg Oral",{"nctId":879,"briefTitle":880,"status":122,"phases":881,"primaryCompletion":675,"completion":206,"start":882,"enrollment":883,"conditions":884,"interventions":886},"NCT05057806","SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan",[88],"2021-01-13",30,[885,200],"Type2 Diabetes",[859],{"nctId":888,"briefTitle":889,"status":122,"phases":890,"primaryCompletion":349,"completion":437,"start":891,"enrollment":892,"conditions":893,"interventions":894},"NCT07053293","SGLT2i, Hepatic Glucose Production, and SNS",[88],"2025-01-07",22,[15],[859],3,{"trials":897,"activeCount":212,"soonestReadout":349},[898,905],{"nctId":899,"briefTitle":900,"status":122,"phases":901,"primaryCompletion":349,"completion":437,"start":902,"enrollment":494,"conditions":903,"interventions":904},"NCT07053306","SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia",[89],"2025-04-29",[15],[859],{"nctId":906,"briefTitle":907,"status":122,"phases":908,"primaryCompletion":349,"completion":437,"start":909,"enrollment":883,"conditions":910,"interventions":911},"NCT05960656","SGLTi, Hepatic Glucose Production and Ketogenesis",[89],"2023-10-05",[15],[859],{"trials":913,"activeCount":101},[],{"trials":915,"activeCount":101},[],{"trials":917,"activeCount":101},[918],{"nctId":919,"briefTitle":920,"status":111,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":928},"NCT03193684","Empagliflozin and Hepatic Glucose Metabolism",[92],"2023-01-30","2024-01-30","2018-05-20",72,[927],"Hepatic Glucose Metabolism",[859,929],"Control",{"trials":931,"activeCount":101},[],{"intervention":229,"totalTrials":484,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":961,"PHASE3":983,"PHASE4":985,"NA":1000},{"trials":935,"activeCount":101},[],{"trials":937,"activeCount":134,"soonestReadout":220},[938,947],{"nctId":939,"briefTitle":940,"status":111,"phases":941,"primaryCompletion":942,"completion":942,"start":943,"enrollment":16,"conditions":944,"interventions":946},"NCT03713801","Impact of Metformin on Immunity",[89],"2024-07-16","2019-01-14",[24,945],"Vaccine Response Impaired",[229],{"nctId":948,"briefTitle":949,"status":122,"phases":950,"primaryCompletion":220,"completion":220,"start":951,"enrollment":952,"conditions":953,"interventions":957},"NCT06446531","Prevention of Progression of Prediabetes, Obesity and CV Risk",[89],"2024-09-11",64,[954,955,956],"Pre-Diabetes","Weight, Body","Cardiovascular Diseases",[958,959,229,960],"Rybelsus","Jardiance 25Mg","Actos",{"trials":962,"activeCount":101},[963,973],{"nctId":964,"briefTitle":965,"status":111,"phases":966,"primaryCompletion":967,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":972},"NCT02570672","Metformin for Preventing Frailty in High-risk Older Adults",[90],"2024-02-07","2016-04",141,[971],"Frailty",[229],{"nctId":974,"briefTitle":975,"status":111,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":982},"NCT01620593","Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer",[90],"2016-07","2016-09","2011-04",41,[26],[229],{"trials":984,"activeCount":101},[],{"trials":986,"activeCount":101},[987,996],{"nctId":988,"briefTitle":989,"status":111,"phases":990,"primaryCompletion":991,"completion":991,"start":992,"enrollment":925,"conditions":993,"interventions":994},"NCT02911792","Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration",[92],"2023-07-11","2016-12-20",[31],[227,229,995],"Glipizide 5 MG",{"nctId":386,"briefTitle":387,"status":111,"phases":997,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":998,"interventions":999},[92],[394],[132,229,396],{"trials":1001,"activeCount":134,"soonestReadout":219},[1002],{"nctId":216,"briefTitle":217,"status":122,"phases":1003,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1004,"interventions":1005},[93],[31,224,225],[227,228,96,229],{"intervention":1007,"totalTrials":212,"cells":1008},"prednisone",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1025,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1010,"activeCount":101},[],{"trials":1012,"activeCount":134,"soonestReadout":55},[1013],{"nctId":53,"briefTitle":54,"status":122,"phases":1014,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1016,"interventions":1018},[89],"2025-06-20",[1017],"Diffuse Large B-cell Lymphoma",[56,1019,1020,1021,1022,1023,1024],"Roflumilast","Rituximab","Cyclophosphamide","Vincristine","Doxorubicin","Prednisone",{"trials":1026,"activeCount":101},[1027],{"nctId":1028,"briefTitle":1029,"status":1030,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1036},"NCT00348816","Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer","TERMINATED",[90],"2016-07-08","2006-05",21,[26],[1037,1007],"docetaxel",{"trials":1039,"activeCount":101},[],{"trials":1041,"activeCount":101},[],{"trials":1043,"activeCount":101},[],{"intervention":1019,"totalTrials":212,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":134,"soonestReadout":55},[1050,1061],{"nctId":1051,"briefTitle":1052,"status":111,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1060},"NCT03458546","Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma",[89],"2021-12-31","2024-01-16","2018-05-21",14,[1059],"Lymphoma, B-Cell",[1019],{"nctId":53,"briefTitle":54,"status":122,"phases":1062,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1063,"interventions":1064},[89],[1017],[56,1019,1020,1021,1022,1023,1024],{"trials":1066,"activeCount":101},[],{"trials":1068,"activeCount":101},[],{"trials":1070,"activeCount":101},[],{"trials":1072,"activeCount":101},[],{"intervention":66,"totalTrials":134,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1076,"activeCount":101},[],{"trials":1078,"activeCount":134,"soonestReadout":65},[1079],{"nctId":63,"briefTitle":64,"status":1080,"phases":1081,"primaryCompletion":65,"completion":219,"start":1082,"enrollment":304,"conditions":1083,"interventions":1086},"ENROLLING_BY_INVITATION",[89],"2022-05-16",[1084,1085],"Suffering, Physical","Nausea",[66,1087,1088],"Mandarin Oil","Peppermint oil",{"trials":1090,"activeCount":101},[],{"trials":1092,"activeCount":101},[],{"trials":1094,"activeCount":101},[],{"trials":1096,"activeCount":101},[],{"intervention":1087,"totalTrials":134,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1107,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1100,"activeCount":101},[],{"trials":1102,"activeCount":134,"soonestReadout":65},[1103],{"nctId":63,"briefTitle":64,"status":1080,"phases":1104,"primaryCompletion":65,"completion":219,"start":1082,"enrollment":304,"conditions":1105,"interventions":1106},[89],[1084,1085],[66,1087,1088],{"trials":1108,"activeCount":101},[],{"trials":1110,"activeCount":101},[],{"trials":1112,"activeCount":101},[],{"trials":1114,"activeCount":101},[],{"intervention":1088,"totalTrials":134,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1118,"activeCount":101},[],{"trials":1120,"activeCount":134,"soonestReadout":65},[1121],{"nctId":63,"briefTitle":64,"status":1080,"phases":1122,"primaryCompletion":65,"completion":219,"start":1082,"enrollment":304,"conditions":1123,"interventions":1124},[89],[1084,1085],[66,1087,1088],{"trials":1126,"activeCount":101},[],{"trials":1128,"activeCount":101},[],{"trials":1130,"activeCount":101},[],{"trials":1132,"activeCount":101},[],{"intervention":1134,"totalTrials":134,"cells":1135},"REMD-477 versus Placebo",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1151,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1137,"activeCount":101},[],{"trials":1139,"activeCount":134,"soonestReadout":1144},[1140],{"nctId":1141,"briefTitle":1142,"status":122,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1150},"NCT07212868","The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery",[89],"2030-05-01","2030-06-30","2026-02-25",150,[1149],"Non-Diabetic",[1134],{"trials":1152,"activeCount":101},[],{"trials":1154,"activeCount":101},[],{"trials":1156,"activeCount":101},[],{"trials":1158,"activeCount":101},[],{"intervention":958,"totalTrials":134,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1175},{"trials":1162,"activeCount":101},[],{"trials":1164,"activeCount":134,"soonestReadout":220},[1165],{"nctId":948,"briefTitle":949,"status":122,"phases":1166,"primaryCompletion":220,"completion":220,"start":951,"enrollment":952,"conditions":1167,"interventions":1168},[89],[954,955,956],[958,959,229,960],{"trials":1170,"activeCount":101},[],{"trials":1172,"activeCount":101},[],{"trials":1174,"activeCount":101},[],{"trials":1176,"activeCount":101},[],{"intervention":959,"totalTrials":134,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1187,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1180,"activeCount":101},[],{"trials":1182,"activeCount":134,"soonestReadout":220},[1183],{"nctId":948,"briefTitle":949,"status":122,"phases":1184,"primaryCompletion":220,"completion":220,"start":951,"enrollment":952,"conditions":1185,"interventions":1186},[89],[954,955,956],[958,959,229,960],{"trials":1188,"activeCount":101},[],{"trials":1190,"activeCount":101},[],{"trials":1192,"activeCount":101},[],{"trials":1194,"activeCount":101},[],{"intervention":960,"totalTrials":134,"cells":1196},{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1198,"activeCount":101},[],{"trials":1200,"activeCount":134,"soonestReadout":220},[1201],{"nctId":948,"briefTitle":949,"status":122,"phases":1202,"primaryCompletion":220,"completion":220,"start":951,"enrollment":952,"conditions":1203,"interventions":1204},[89],[954,955,956],[958,959,229,960],{"trials":1206,"activeCount":101},[],{"trials":1208,"activeCount":101},[],{"trials":1210,"activeCount":101},[],{"trials":1212,"activeCount":101},[],{"intervention":1214,"totalTrials":134,"cells":1215},"Empagliflozin 25 MG plus Pioglitazone placebo",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":134,"soonestReadout":349},[1220],{"nctId":1221,"briefTitle":1222,"status":122,"phases":1223,"primaryCompletion":349,"completion":437,"start":1224,"enrollment":952,"conditions":1225,"interventions":1226},"NCT07053319","SGLT2i, Pioglitazone, and Ketone Production in T2D",[89],"2026-05-11",[15],[1214,1227,1228,1229],"Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo","Empagliflozin 25 mg\u002Fd plus Pioglitazone","Pioglitazone placebo + Empagliflozin placebo",{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[],{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"intervention":1227,"totalTrials":134,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1248,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1241,"activeCount":101},[],{"trials":1243,"activeCount":134,"soonestReadout":349},[1244],{"nctId":1221,"briefTitle":1222,"status":122,"phases":1245,"primaryCompletion":349,"completion":437,"start":1224,"enrollment":952,"conditions":1246,"interventions":1247},[89],[15],[1214,1227,1228,1229],{"trials":1249,"activeCount":101},[],{"trials":1251,"activeCount":101},[],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":101},[],{"intervention":1228,"totalTrials":134,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":134,"soonestReadout":349},[1262],{"nctId":1221,"briefTitle":1222,"status":122,"phases":1263,"primaryCompletion":349,"completion":437,"start":1224,"enrollment":952,"conditions":1264,"interventions":1265},[89],[15],[1214,1227,1228,1229],{"trials":1267,"activeCount":101},[],{"trials":1269,"activeCount":101},[],{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[],{"intervention":1229,"totalTrials":134,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1284,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1277,"activeCount":101},[],{"trials":1279,"activeCount":134,"soonestReadout":349},[1280],{"nctId":1221,"briefTitle":1222,"status":122,"phases":1281,"primaryCompletion":349,"completion":437,"start":1224,"enrollment":952,"conditions":1282,"interventions":1283},[89],[15],[1214,1227,1228,1229],{"trials":1285,"activeCount":101},[],{"trials":1287,"activeCount":101},[],{"trials":1289,"activeCount":101},[],{"trials":1291,"activeCount":101},[],{"intervention":56,"totalTrials":134,"cells":1293},{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1295,"activeCount":101},[],{"trials":1297,"activeCount":134,"soonestReadout":55},[1298],{"nctId":53,"briefTitle":54,"status":122,"phases":1299,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1300,"interventions":1301},[89],[1017],[56,1019,1020,1021,1022,1023,1024],{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":101},[],{"trials":1309,"activeCount":101},[],{"intervention":1020,"totalTrials":134,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1313,"activeCount":101},[],{"trials":1315,"activeCount":134,"soonestReadout":55},[1316],{"nctId":53,"briefTitle":54,"status":122,"phases":1317,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1318,"interventions":1319},[89],[1017],[56,1019,1020,1021,1022,1023,1024],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":101},[],{"trials":1327,"activeCount":101},[],{"intervention":1021,"totalTrials":134,"cells":1329},{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1331,"activeCount":101},[],{"trials":1333,"activeCount":134,"soonestReadout":55},[1334],{"nctId":53,"briefTitle":54,"status":122,"phases":1335,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1336,"interventions":1337},[89],[1017],[56,1019,1020,1021,1022,1023,1024],{"trials":1339,"activeCount":101},[],{"trials":1341,"activeCount":101},[],{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":101},[],{"intervention":1022,"totalTrials":134,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1349,"activeCount":101},[],{"trials":1351,"activeCount":134,"soonestReadout":55},[1352],{"nctId":53,"briefTitle":54,"status":122,"phases":1353,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1354,"interventions":1355},[89],[1017],[56,1019,1020,1021,1022,1023,1024],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"trials":1361,"activeCount":101},[],{"trials":1363,"activeCount":101},[],{"intervention":1023,"totalTrials":134,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1374,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":134,"soonestReadout":55},[1370],{"nctId":53,"briefTitle":54,"status":122,"phases":1371,"primaryCompletion":55,"completion":80,"start":1015,"enrollment":97,"conditions":1372,"interventions":1373},[89],[1017],[56,1019,1020,1021,1022,1023,1024],{"trials":1375,"activeCount":101},[],{"trials":1377,"activeCount":101},[],{"trials":1379,"activeCount":101},[],{"trials":1381,"activeCount":101},[],{"intervention":1383,"totalTrials":134,"cells":1384},"Avasopasem",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1406},{"trials":1386,"activeCount":101},[],{"trials":1388,"activeCount":134,"soonestReadout":1393},[1389],{"nctId":1390,"briefTitle":1391,"status":122,"phases":1392,"primaryCompletion":1393,"completion":1394,"start":1395,"enrollment":1396,"conditions":1397,"interventions":1399},"NCT07137871","Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4\u002F6 Inhibitor and Hormonal Therapy",[89],"2027-10","2028-10","2025-10-02",35,[1398],"Breast Cancer Metastatic",[1383],{"trials":1401,"activeCount":101},[],{"trials":1403,"activeCount":101},[],{"trials":1405,"activeCount":101},[],{"trials":1407,"activeCount":101},[],{"intervention":86,"totalTrials":895,"cells":1409},{"EARLY_PHASE1":1410,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1411,"activeCount":895,"soonestReadout":85},[1412,1423,1433],{"nctId":83,"briefTitle":84,"status":122,"phases":1413,"primaryCompletion":85,"completion":1414,"start":1415,"enrollment":304,"conditions":1416,"interventions":1421},[88],"2027-08","2015-07",[1417,1418,1419,1420],"Post Bariatric Surgery","Gastric Bypass","Sleeve Gastrectomy","Hypoglycemia After Gastric Bypass",[86,1422],"Atropine",{"nctId":1424,"briefTitle":1425,"status":122,"phases":1426,"primaryCompletion":85,"completion":1414,"start":172,"enrollment":1427,"conditions":1428,"interventions":1430},"NCT01803451","Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass",[88],80,[1429],"Post-bariatric Surgery",[1431,1432],"exendin-","exendin -",{"nctId":1434,"briefTitle":1435,"status":122,"phases":1436,"primaryCompletion":85,"completion":1414,"start":391,"enrollment":1437,"conditions":1438,"interventions":1441},"NCT00992901","Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery",[88],160,[1439,1440],"Post Bariatricsurgery","Hypoglycemia",[86,1422,1442],"GLP-1 and GIP",{"trials":1444,"activeCount":101},[],{"trials":1446,"activeCount":101},[],{"trials":1448,"activeCount":101},[],{"trials":1450,"activeCount":101},[],{"trials":1452,"activeCount":101},[],{"intervention":1422,"totalTrials":212,"cells":1454},{"EARLY_PHASE1":1455,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1456,"activeCount":212,"soonestReadout":85},[1457,1461],{"nctId":83,"briefTitle":84,"status":122,"phases":1458,"primaryCompletion":85,"completion":1414,"start":1415,"enrollment":304,"conditions":1459,"interventions":1460},[88],[1417,1418,1419,1420],[86,1422],{"nctId":1434,"briefTitle":1435,"status":122,"phases":1462,"primaryCompletion":85,"completion":1414,"start":391,"enrollment":1437,"conditions":1463,"interventions":1464},[88],[1439,1440],[86,1422,1442],{"trials":1466,"activeCount":101},[],{"trials":1468,"activeCount":101},[],{"trials":1470,"activeCount":101},[],{"trials":1472,"activeCount":101},[],{"trials":1474,"activeCount":101},[],{"intervention":71,"totalTrials":212,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1478,"activeCount":212,"soonestReadout":70},[1479,1490],{"nctId":1480,"briefTitle":1481,"status":435,"phases":1482,"primaryCompletion":1483,"completion":1484,"start":677,"enrollment":351,"conditions":1485,"interventions":1488},"NCT07437053","Sarcopenia in Chronic Kidney Disease (CKD) Patients",[88],"2027-07-31","2027-10-30",[1486,1487],"Chronic Kidney Disease","Sarcopenia",[71,1489],"EEA",{"nctId":68,"briefTitle":69,"status":122,"phases":1491,"primaryCompletion":70,"completion":219,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1495},[88],"2024-10-18",28,[679],[71,1489],{"trials":1497,"activeCount":101},[],{"trials":1499,"activeCount":101},[],{"trials":1501,"activeCount":101},[],{"trials":1503,"activeCount":101},[],{"trials":1505,"activeCount":101},[],{"intervention":1489,"totalTrials":212,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1509,"activeCount":212,"soonestReadout":70},[1510,1514],{"nctId":1480,"briefTitle":1481,"status":435,"phases":1511,"primaryCompletion":1483,"completion":1484,"start":677,"enrollment":351,"conditions":1512,"interventions":1513},[88],[1486,1487],[71,1489],{"nctId":68,"briefTitle":69,"status":122,"phases":1515,"primaryCompletion":70,"completion":219,"start":1492,"enrollment":1493,"conditions":1516,"interventions":1517},[88],[679],[71,1489],{"trials":1519,"activeCount":101},[],{"trials":1521,"activeCount":101},[],{"trials":1523,"activeCount":101},[],{"trials":1525,"activeCount":101},[],{"trials":1527,"activeCount":101},[],{"intervention":1529,"totalTrials":212,"cells":1530},"Tranexamic Acid Injectable Product",{"EARLY_PHASE1":1531,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1532,"activeCount":212,"soonestReadout":1537},[1533,1544],{"nctId":1534,"briefTitle":1535,"status":122,"phases":1536,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":22,"conditions":1540,"interventions":1543},"NCT06580509","TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study",[88],"2027-09-30","2028-09-30","2026-02-18",[1541,1542],"Hemorrhage, Surgical","Tonsillar Bleeding",[1529],{"nctId":1545,"briefTitle":1546,"status":435,"phases":1547,"primaryCompletion":1537,"completion":1538,"start":75,"enrollment":883,"conditions":1548,"interventions":1549},"NCT07565753","TEAPOT Study Multisite",[88],[1541,1542],[1529],{"trials":1551,"activeCount":101},[],{"trials":1553,"activeCount":101},[],{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":101},[],{"trials":1559,"activeCount":101},[],{"intervention":877,"totalTrials":134,"cells":1561},{"EARLY_PHASE1":1562,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1576},{"trials":1563,"activeCount":134,"soonestReadout":868},[1564],{"nctId":865,"briefTitle":866,"status":122,"phases":1565,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":1566,"interventions":1567},[88],[873,874],[876,877],{"trials":1569,"activeCount":101},[],{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"trials":1575,"activeCount":101},[],{"trials":1577,"activeCount":101},[],{"intervention":1579,"totalTrials":134,"cells":1580},"MCAM",{"EARLY_PHASE1":1581,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1582,"activeCount":134,"soonestReadout":1587},[1583],{"nctId":1584,"briefTitle":1585,"status":435,"phases":1586,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":186,"conditions":1590,"interventions":1592},"NCT07602335","Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants and Onset and Duration of μ-Opioid Receptor Blockade by MCAM in Healthy, Adult, Opioid-Experienced Participants",[88],"2027-05-31","2027-11-30","2026-07-08",[1591],"Opioid Use Disorder",[1579],{"trials":1594,"activeCount":101},[],{"trials":1596,"activeCount":101},[],{"trials":1598,"activeCount":101},[],{"trials":1600,"activeCount":101},[],{"trials":1602,"activeCount":101},[],{"intervention":81,"totalTrials":134,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1606,"activeCount":134,"soonestReadout":80},[1607],{"nctId":78,"briefTitle":79,"status":122,"phases":1608,"primaryCompletion":80,"completion":411,"start":1055,"enrollment":97,"conditions":1609,"interventions":1611},[88],[15,1610],"Heart Failure, Reduced Ejection Fraction",[81],{"trials":1613,"activeCount":101},[],{"trials":1615,"activeCount":101},[],{"trials":1617,"activeCount":101},[],{"trials":1619,"activeCount":101},[],{"trials":1621,"activeCount":101},[],{"intervention":46,"totalTrials":134,"cells":1623},{"EARLY_PHASE1":1624,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1625,"activeCount":134,"soonestReadout":45},[1626],{"nctId":43,"briefTitle":44,"status":697,"phases":1627,"primaryCompletion":45,"completion":1628,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1633},[88],"2025-12-02","2017-01-31",51,[1632],"Colon Cancer",[46],{"trials":1635,"activeCount":101},[],{"trials":1637,"activeCount":101},[],{"trials":1639,"activeCount":101},[],{"trials":1641,"activeCount":101},[],{"trials":1643,"activeCount":101},[],{"intervention":1432,"totalTrials":134,"cells":1645},{"EARLY_PHASE1":1646,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1647,"activeCount":134,"soonestReadout":85},[1648],{"nctId":1424,"briefTitle":1425,"status":122,"phases":1649,"primaryCompletion":85,"completion":1414,"start":172,"enrollment":1427,"conditions":1650,"interventions":1651},[88],[1429],[1431,1432],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":101},[],{"trials":1659,"activeCount":101},[],{"trials":1661,"activeCount":101},[],{"intervention":1442,"totalTrials":134,"cells":1663},{"EARLY_PHASE1":1664,"PHASE1":1670,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1665,"activeCount":134,"soonestReadout":85},[1666],{"nctId":1434,"briefTitle":1435,"status":122,"phases":1667,"primaryCompletion":85,"completion":1414,"start":391,"enrollment":1437,"conditions":1668,"interventions":1669},[88],[1439,1440],[86,1422,1442],{"trials":1671,"activeCount":101},[],{"trials":1673,"activeCount":101},[],{"trials":1675,"activeCount":101},[],{"trials":1677,"activeCount":101},[],{"trials":1679,"activeCount":101},[],{"intervention":507,"totalTrials":895,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1683,"activeCount":134,"soonestReadout":502},[1684],{"nctId":499,"briefTitle":500,"status":122,"phases":1685,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":1686,"interventions":1687},[88],[24],[51,507],{"trials":1689,"activeCount":101},[],{"trials":1691,"activeCount":101},[],{"trials":1693,"activeCount":101},[],{"trials":1695,"activeCount":101},[],{"trials":1697,"activeCount":101},[1698,1706],{"nctId":1699,"briefTitle":1700,"status":1701,"phases":1702,"conditions":1703,"interventions":1705},"NCT03493152","Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)","NO_LONGER_AVAILABLE",[],[1704],"Gastrointestinal Stromal Tumor",[507],{"nctId":1707,"briefTitle":1708,"status":1701,"phases":1709,"conditions":1710,"interventions":1712},"NCT03493165","Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)",[],[1711],"Uterine Sarcoma",[507],{"intervention":227,"totalTrials":32,"cells":1714},{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1721,"PHASE4":1743,"NA":1779},{"trials":1716,"activeCount":101},[],{"trials":1718,"activeCount":101},[],{"trials":1720,"activeCount":101},[],{"trials":1722,"activeCount":101},[1723,1733],{"nctId":1724,"briefTitle":1725,"status":111,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":883,"conditions":1730,"interventions":1732},"NCT02592421","SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2",[91],"2018-10-01","2019-10-31","2015-10-23",[1731],"Type II Diabetes Mellitus",[227],{"nctId":1734,"briefTitle":1735,"status":111,"phases":1736,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":883,"conditions":1740,"interventions":1742},"NCT02984644","Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin",[91],"2018-11-16","2019-11-16","2017-09-06",[1741],"Type II; Diabetes",[227],{"trials":1744,"activeCount":101},[1745,1756,1760,1769],{"nctId":1746,"briefTitle":1747,"status":111,"phases":1748,"primaryCompletion":1749,"completion":1750,"start":1751,"enrollment":1752,"conditions":1753,"interventions":1754},"NCT03331289","Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria",[92],"2022-03-31","2022-11-04","2018-02-28",107,[31],[158,227,1755],"Exenatide and Dapagliflozin",{"nctId":988,"briefTitle":989,"status":111,"phases":1757,"primaryCompletion":991,"completion":991,"start":992,"enrollment":925,"conditions":1758,"interventions":1759},[92],[31],[227,229,995],{"nctId":1761,"briefTitle":1762,"status":111,"phases":1763,"primaryCompletion":1764,"completion":1765,"start":1766,"enrollment":592,"conditions":1767,"interventions":1768},"NCT02981966","Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects",[92],"2022-04-30","2023-05-31","2019-05-23",[31],[227],{"nctId":1770,"briefTitle":1771,"status":111,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1776,"conditions":1777,"interventions":1778},"NCT02981069","Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM",[92],"2022-07-14","2023-03-19","2017-12-15",90,[31],[227,158],{"trials":1780,"activeCount":134,"soonestReadout":219},[1781,1790,1794],{"nctId":1782,"briefTitle":1783,"status":111,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT02613897","ESR-15-11293 - Saxa\u002FDapa, Safety and Efficacy Study",[93],"2018-06-30","2016-01",56,[31],[228,227],{"nctId":216,"briefTitle":217,"status":122,"phases":1791,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1792,"interventions":1793},[93],[31,224,225],[227,228,96,229],{"nctId":1795,"briefTitle":1796,"status":111,"phases":1797,"primaryCompletion":1785,"completion":1785,"start":1798,"enrollment":16,"conditions":1799,"interventions":1802},"NCT01439854","Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling\u002FAction",[93],"2011-03",[1800,1801],"Insulin Sensitivity","Multiple Mitochondrial Dysfunctions Syndrome",[227],{"intervention":228,"totalTrials":212,"cells":1804},{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1806,"activeCount":101},[],{"trials":1808,"activeCount":101},[],{"trials":1810,"activeCount":101},[],{"trials":1812,"activeCount":101},[],{"trials":1814,"activeCount":101},[],{"trials":1816,"activeCount":134,"soonestReadout":219},[1817,1821],{"nctId":1782,"briefTitle":1783,"status":111,"phases":1818,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1787,"conditions":1819,"interventions":1820},[93],[31],[228,227],{"nctId":216,"briefTitle":217,"status":122,"phases":1822,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1823,"interventions":1824},[93],[31,224,225],[227,228,96,229],{"intervention":1826,"totalTrials":134,"cells":1827},"Genetic screening",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[],{"trials":1833,"activeCount":101},[],{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":134,"soonestReadout":1844},[1840],{"nctId":1841,"briefTitle":1842,"status":122,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1856},"NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions",[],"2030-12-31","2005-10-19",2000,[1848,1849,1850,1851,1852,1853,1854,1855],"Pheochromocytoma","Paraganglioma","Inherited Cancer Syndrome","Associated Conditions","Kidney Neoplasms","Bone Cancer","Thyroid Neoplasms","Other Cancer",[1826],{"intervention":1858,"totalTrials":134,"cells":1859},"DNA or RNA Sequencing",{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1866,"PHASE4":1868,"NA":1870},{"trials":1861,"activeCount":101},[],{"trials":1863,"activeCount":101},[],{"trials":1865,"activeCount":101},[],{"trials":1867,"activeCount":101},[],{"trials":1869,"activeCount":101},[],{"trials":1871,"activeCount":134,"soonestReadout":1876},[1872],{"nctId":1873,"briefTitle":1874,"status":435,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1879,"conditions":1880,"interventions":1883},"NCT04620278","Genetic Investigation of Cancer Predisposition",[],"2030-06","2035-12","2026-10",100,[1881,1882],"Genetic Predisposition","Cancer",[1858],{"intervention":158,"totalTrials":1885,"cells":1886},4,{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1915},{"trials":1888,"activeCount":101},[],{"trials":1890,"activeCount":101},[],{"trials":1892,"activeCount":101},[],{"trials":1894,"activeCount":101},[],{"trials":1896,"activeCount":101},[1897,1901,1905,1911],{"nctId":149,"briefTitle":150,"status":111,"phases":1898,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":1899,"interventions":1900},[92],[15,156,117],[96,158,159],{"nctId":1746,"briefTitle":1747,"status":111,"phases":1902,"primaryCompletion":1749,"completion":1750,"start":1751,"enrollment":1752,"conditions":1903,"interventions":1904},[92],[31],[158,227,1755],{"nctId":1906,"briefTitle":1907,"status":111,"phases":1908,"primaryCompletion":1415,"completion":1415,"start":152,"enrollment":19,"conditions":1909,"interventions":1910},"NCT01588418","Acute Effect of Exenatide on Brain Glucose Metabolism",[92],[224,394],[158],{"nctId":1770,"briefTitle":1771,"status":111,"phases":1912,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1776,"conditions":1913,"interventions":1914},[92],[31],[227,158],{"trials":1916,"activeCount":101},[],{"intervention":256,"totalTrials":895,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1953},{"trials":1920,"activeCount":101},[],{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[],{"trials":1926,"activeCount":101},[],{"trials":1928,"activeCount":101},[1929,1933,1945],{"nctId":244,"briefTitle":245,"status":111,"phases":1930,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":1931,"interventions":1932},[92],[251,252],[254,255,256,231],{"nctId":1934,"briefTitle":1935,"status":111,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1943},"NCT00183469","Maintenance Treatment of Bipolar Depression",[92],"2009-02","2009-04","2004-12",86,[29,1942],"Depression",[256,1944],"Divalproex (DIV) ER",{"nctId":1946,"briefTitle":1947,"status":111,"phases":1948,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1493,"conditions":1951,"interventions":1952},"NCT00223509","Lamictal As Add on Treatment in Mixed States of Bipolar Disorder",[92],"2007-11","2005-08",[29],[256],{"trials":1954,"activeCount":101},[],{"intervention":1956,"totalTrials":212,"cells":1957},"Risperidone",{"EARLY_PHASE1":1958,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1988},{"trials":1959,"activeCount":101},[1960],{"nctId":1961,"briefTitle":1962,"status":111,"phases":1963,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":19,"conditions":1967,"interventions":1969},"NCT04587115","Reducing the Abuse Liability of Prescription Opioids",[88],"2019-06-01","2020-01-01","2017-06-16",[1968],"Addiction",[1956,1970,1971],"Ziprasidone","Oxycodone",{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[1980],{"nctId":1981,"briefTitle":1982,"status":111,"phases":1983,"primaryCompletion":1984,"completion":1984,"start":185,"enrollment":1985,"conditions":1986,"interventions":1987},"NCT00294255","Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania",[92],"2006-10",45,[29],[1956],{"trials":1989,"activeCount":101},[],{"intervention":1991,"totalTrials":134,"cells":1992},"Canagliflozin 300mg",{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":1999,"PHASE4":2001,"NA":2012},{"trials":1994,"activeCount":101},[],{"trials":1996,"activeCount":101},[],{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[2003],{"nctId":2004,"briefTitle":2005,"status":541,"phases":2006,"primaryCompletion":2007,"completion":2007,"start":2008,"enrollment":101,"conditions":2009,"interventions":2011},"NCT03190798","Effects of Canagliflozin on Intravascular Volume and Hemodynamics",[92],"2018-08-01","2017-09-01",[2010,956],"Type2 Diabetes Mellitus",[1991],{"trials":2013,"activeCount":101},[],{"intervention":2015,"totalTrials":134,"cells":2016},"Finasteride",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2037},{"trials":2018,"activeCount":101},[],{"trials":2020,"activeCount":101},[],{"trials":2022,"activeCount":101},[],{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[2027],{"nctId":2028,"briefTitle":2029,"status":111,"phases":2030,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":2035,"interventions":2036},"NCT01296672","3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer",[92],"2016-11","2017-01","2011-02",383,[26],[2015],{"trials":2038,"activeCount":101},[],{"intervention":159,"totalTrials":134,"cells":2040},{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2049,"NA":2055},{"trials":2042,"activeCount":101},[],{"trials":2044,"activeCount":101},[],{"trials":2046,"activeCount":101},[],{"trials":2048,"activeCount":101},[],{"trials":2050,"activeCount":101},[2051],{"nctId":149,"briefTitle":150,"status":111,"phases":2052,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":2053,"interventions":2054},[92],[15,156,117],[96,158,159],{"trials":2056,"activeCount":101},[],{"intervention":1755,"totalTrials":134,"cells":2058},{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2067,"NA":2073},{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[],{"trials":2064,"activeCount":101},[],{"trials":2066,"activeCount":101},[],{"trials":2068,"activeCount":101},[2069],{"nctId":1746,"briefTitle":1747,"status":111,"phases":2070,"primaryCompletion":1749,"completion":1750,"start":1751,"enrollment":1752,"conditions":2071,"interventions":2072},[92],[31],[158,227,1755],{"trials":2074,"activeCount":101},[],{"intervention":2076,"totalTrials":134,"cells":2077},"Cycloset",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2097},{"trials":2079,"activeCount":101},[],{"trials":2081,"activeCount":101},[],{"trials":2083,"activeCount":101},[],{"trials":2085,"activeCount":101},[],{"trials":2087,"activeCount":101},[2088],{"nctId":2089,"briefTitle":2090,"status":111,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":2094,"conditions":2095,"interventions":2096},"NCT02299050","Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy",[92],"2018-04-30","2014-06",23,[15],[2076],{"trials":2098,"activeCount":101},[],{"intervention":2100,"totalTrials":134,"cells":2101},"metformin\\pioglitazone\\exenatide",{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2122},{"trials":2103,"activeCount":101},[],{"trials":2105,"activeCount":101},[],{"trials":2107,"activeCount":101},[],{"trials":2109,"activeCount":101},[],{"trials":2111,"activeCount":101},[2112],{"nctId":2113,"briefTitle":2114,"status":111,"phases":2115,"primaryCompletion":2116,"completion":2116,"start":2117,"enrollment":2118,"conditions":2119,"interventions":2120},"NCT01107717","Durability of Combination Therapy With Exenatide\u002FPioglitazone\u002FMetformin vs. Conventional Therapy in New Onset T2DM",[92],"2023-02-03","2009-01",318,[394],[2100,2121],"metformin, glyburide and glargine",{"trials":2123,"activeCount":101},[],{"intervention":2121,"totalTrials":134,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2140},{"trials":2127,"activeCount":101},[],{"trials":2129,"activeCount":101},[],{"trials":2131,"activeCount":101},[],{"trials":2133,"activeCount":101},[],{"trials":2135,"activeCount":101},[2136],{"nctId":2113,"briefTitle":2114,"status":111,"phases":2137,"primaryCompletion":2116,"completion":2116,"start":2117,"enrollment":2118,"conditions":2138,"interventions":2139},[92],[394],[2100,2121],{"trials":2141,"activeCount":101},[],{"intervention":2143,"totalTrials":134,"cells":2144},"Spironolactone",{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2164},{"trials":2146,"activeCount":101},[],{"trials":2148,"activeCount":101},[],{"trials":2150,"activeCount":101},[],{"trials":2152,"activeCount":101},[],{"trials":2154,"activeCount":101},[2155],{"nctId":2156,"briefTitle":2157,"status":541,"phases":2158,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":101,"conditions":2161,"interventions":2163},"NCT02429388","High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure",[92],"2015-10","2014-05",[2162],"Heart Failure",[2143],{"trials":2165,"activeCount":101},[],{"intervention":254,"totalTrials":134,"cells":2167},{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2174,"PHASE4":2176,"NA":2182},{"trials":2169,"activeCount":101},[],{"trials":2171,"activeCount":101},[],{"trials":2173,"activeCount":101},[],{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[2178],{"nctId":244,"briefTitle":245,"status":111,"phases":2179,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":2180,"interventions":2181},[92],[251,252],[254,255,256,231],{"trials":2183,"activeCount":101},[],{"intervention":255,"totalTrials":134,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2194,"NA":2200},{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[2196],{"nctId":244,"briefTitle":245,"status":111,"phases":2197,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":2198,"interventions":2199},[92],[251,252],[254,255,256,231],{"trials":2201,"activeCount":101},[],{"intervention":995,"totalTrials":134,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2218},{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"trials":2209,"activeCount":101},[],{"trials":2211,"activeCount":101},[],{"trials":2213,"activeCount":101},[2214],{"nctId":988,"briefTitle":989,"status":111,"phases":2215,"primaryCompletion":991,"completion":991,"start":992,"enrollment":925,"conditions":2216,"interventions":2217},[92],[31],[227,229,995],{"trials":2219,"activeCount":101},[],{"intervention":2221,"totalTrials":134,"cells":2222},"quetiapine SR",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2242},{"trials":2224,"activeCount":101},[],{"trials":2226,"activeCount":101},[],{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"trials":2232,"activeCount":101},[2233],{"nctId":2234,"briefTitle":2235,"status":111,"phases":2236,"primaryCompletion":2237,"completion":248,"start":2238,"enrollment":1493,"conditions":2239,"interventions":2240},"NCT01195363","Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder",[92],"2010-12","2007-04",[29],[2221,2241],"quetiapine sr placebo",{"trials":2243,"activeCount":101},[],{"intervention":2241,"totalTrials":134,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2260},{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[],{"trials":2253,"activeCount":101},[],{"trials":2255,"activeCount":101},[2256],{"nctId":2234,"briefTitle":2235,"status":111,"phases":2257,"primaryCompletion":2237,"completion":248,"start":2238,"enrollment":1493,"conditions":2258,"interventions":2259},[92],[29],[2221,2241],{"trials":2261,"activeCount":101},[],{"intervention":2263,"totalTrials":134,"cells":2264},"Semaglutide Injectable Product",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2285},{"trials":2266,"activeCount":101},[],{"trials":2268,"activeCount":101},[],{"trials":2270,"activeCount":101},[],{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":101},[2275],{"nctId":2276,"briefTitle":2277,"status":111,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":351,"conditions":2281,"interventions":2284},"NCT05786521","Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults",[92],"2024-05-20","2023-04-01",[24,31,2282,2283],"PreDiabetes","Overweight and Obesity",[2263],{"trials":2286,"activeCount":101},[],{"intervention":2288,"totalTrials":134,"cells":2289},"Sertraline",{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2310},{"trials":2291,"activeCount":101},[],{"trials":2293,"activeCount":101},[],{"trials":2295,"activeCount":101},[],{"trials":2297,"activeCount":101},[],{"trials":2299,"activeCount":101},[2300],{"nctId":2301,"briefTitle":2302,"status":111,"phases":2303,"primaryCompletion":2304,"completion":247,"start":979,"enrollment":2305,"conditions":2306,"interventions":2309},"NCT02504931","Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems",[92],"2016-08",49,[2307,2308],"PTSD","Alcohol Use Disorder",[2288],{"trials":2311,"activeCount":101},[],{"intervention":2313,"totalTrials":134,"cells":2314},"Dapagliflozin 10mg then Placebo Oral",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2323,"NA":2334},{"trials":2316,"activeCount":101},[],{"trials":2318,"activeCount":101},[],{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[2325],{"nctId":2326,"briefTitle":2327,"status":111,"phases":2328,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":518,"conditions":2332,"interventions":2333},"NCT03168295","PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria",[92],"2018-10","2019-05-15","2016-10",[31],[2313],{"trials":2335,"activeCount":101},[],{"intervention":2337,"totalTrials":134,"cells":2338},"simvastatin",{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2345,"PHASE4":2347,"NA":2359},{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":101},[],{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[2349],{"nctId":2350,"briefTitle":2351,"status":541,"phases":2352,"primaryCompletion":2353,"completion":2353,"start":2354,"enrollment":101,"conditions":2355,"interventions":2358},"NCT00946166","Impact of Statins on Cytokine Expression in Pneumonia",[92],"2011-08","2009-07",[2356,2357],"Community Acquired Pneumonia","Cardiovascular Risk Factors",[2337],{"trials":2360,"activeCount":101},[],{"intervention":2362,"totalTrials":134,"cells":2363},"Guanfacine Extended Release",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2383},{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":101},[],{"trials":2369,"activeCount":101},[],{"trials":2371,"activeCount":101},[],{"trials":2373,"activeCount":101},[2374],{"nctId":2375,"briefTitle":2376,"status":111,"phases":2377,"primaryCompletion":2353,"completion":2353,"start":2378,"enrollment":2379,"conditions":2380,"interventions":2382},"NCT01069523","Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)",[92],"2010-03",42,[2381],"Attention Deficit Disorder With Hyperactivity",[2362],{"trials":2384,"activeCount":101},[],{"intervention":1944,"totalTrials":134,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2395,"NA":2401},{"trials":2388,"activeCount":101},[],{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[],{"trials":2396,"activeCount":101},[2397],{"nctId":1934,"briefTitle":1935,"status":111,"phases":2398,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":2399,"interventions":2400},[92],[29,1942],[256,1944],{"trials":2402,"activeCount":101},[],{"intervention":929,"totalTrials":134,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2411,"PHASE4":2413,"NA":2419},{"trials":2406,"activeCount":101},[],{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[],{"trials":2412,"activeCount":101},[],{"trials":2414,"activeCount":101},[2415],{"nctId":919,"briefTitle":920,"status":111,"phases":2416,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":2417,"interventions":2418},[92],[927],[859,929],{"trials":2420,"activeCount":101},[],{"intervention":2422,"totalTrials":134,"cells":2423},"Provodine",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2446},{"trials":2425,"activeCount":101},[],{"trials":2427,"activeCount":101},[],{"trials":2429,"activeCount":101},[],{"trials":2431,"activeCount":101},[],{"trials":2433,"activeCount":101},[2434],{"nctId":2435,"briefTitle":2436,"status":111,"phases":2437,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":2442,"interventions":2445},"NCT02600871","Skin and Soft Tissue Infection (SSTI) Study",[92],"2017-04-30","2017-05-30","2015-12",101,[2443,2444],"Skin Diseases, Infectious","Soft Tissue Infections",[2422],{"trials":2447,"activeCount":101},[],{"intervention":2449,"totalTrials":134,"cells":2450},"Misoprostol 200Mcg Tab",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2457,"PHASE4":2459,"NA":2470},{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[],{"trials":2458,"activeCount":101},[],{"trials":2460,"activeCount":101},[2461],{"nctId":2462,"briefTitle":2463,"status":111,"phases":2464,"primaryCompletion":2465,"completion":2465,"start":2466,"enrollment":16,"conditions":2467,"interventions":2469},"NCT03064568","Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy",[92],"2024-06-18","2016-10-14",[2468],"Myomectomy; Surgical Blood Loss",[2449],{"trials":2471,"activeCount":101},[],{"intervention":2473,"totalTrials":134,"cells":2474},"methylphenidate-OROS",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2492},{"trials":2476,"activeCount":101},[],{"trials":2478,"activeCount":101},[],{"trials":2480,"activeCount":101},[],{"trials":2482,"activeCount":101},[],{"trials":2484,"activeCount":101},[2485],{"nctId":2486,"briefTitle":2487,"status":111,"phases":2488,"primaryCompletion":2237,"completion":2237,"start":184,"enrollment":2489,"conditions":2490,"interventions":2491},"NCT00778310","Neuroimaging of the Effects of Concerta in the Treatment of ADHD",[92],76,[2381],[2473],{"trials":2493,"activeCount":101},[],{"intervention":2495,"totalTrials":134,"cells":2496},"iloperidone",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2514},{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[],{"trials":2502,"activeCount":101},[],{"trials":2504,"activeCount":101},[],{"trials":2506,"activeCount":101},[2507],{"nctId":2508,"briefTitle":2509,"status":111,"phases":2510,"primaryCompletion":2511,"completion":2511,"start":493,"enrollment":980,"conditions":2512,"interventions":2513},"NCT02413918","Iloperidone in Mixed States of Bipolar Disorder",[92],"2015-04",[29],[2495],{"trials":2515,"activeCount":101},[],{"intervention":396,"totalTrials":134,"cells":2517},{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2524,"PHASE4":2526,"NA":2532},{"trials":2519,"activeCount":101},[],{"trials":2521,"activeCount":101},[],{"trials":2523,"activeCount":101},[],{"trials":2525,"activeCount":101},[],{"trials":2527,"activeCount":101},[2528],{"nctId":386,"briefTitle":387,"status":111,"phases":2529,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":2530,"interventions":2531},[92],[394],[132,229,396],{"trials":2533,"activeCount":101},[],{"intervention":2535,"totalTrials":134,"cells":2536},"acetaminophen, IV preparation",{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2557},{"trials":2538,"activeCount":101},[],{"trials":2540,"activeCount":101},[],{"trials":2542,"activeCount":101},[],{"trials":2544,"activeCount":101},[],{"trials":2546,"activeCount":101},[2547],{"nctId":2548,"briefTitle":2549,"status":541,"phases":2550,"primaryCompletion":2093,"completion":2093,"start":2551,"enrollment":101,"conditions":2552,"interventions":2556},"NCT02056678","Outcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA",[92],"2014-02",[2553,2554,2555],"Cholecystitis","Cholelithiasis","Obstructive Sleep Apnea",[2535],{"trials":2558,"activeCount":101},[],{"intervention":2560,"totalTrials":134,"cells":2561},"Amiodarone",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2583},{"trials":2563,"activeCount":101},[],{"trials":2565,"activeCount":101},[],{"trials":2567,"activeCount":101},[],{"trials":2569,"activeCount":101},[],{"trials":2571,"activeCount":101},[2572],{"nctId":2573,"briefTitle":2574,"status":1030,"phases":2575,"primaryCompletion":2576,"completion":2576,"start":2577,"enrollment":32,"conditions":2578,"interventions":2582},"NCT02668432","Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock",[92],"2018-09-20","2016-05",[2579,2580,2581],"New Onset Atrial Fibrillation","Severe Sepsis","Septic Shock",[2560],{"trials":2584,"activeCount":101},[],{"intervention":2586,"totalTrials":134,"cells":2587},"Botulinum toxin type B",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2594,"PHASE4":2606,"NA":2608},{"trials":2589,"activeCount":101},[],{"trials":2591,"activeCount":101},[],{"trials":2593,"activeCount":101},[],{"trials":2595,"activeCount":101},[2596],{"nctId":2597,"briefTitle":2598,"status":111,"phases":2599,"completion":2600,"start":2601,"enrollment":351,"conditions":2602,"interventions":2605},"NCT00125203","Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)",[90,91],"2007-08","2003-07",[2603,2604],"Amyotrophic Lateral Sclerosis","Sialorrhea",[2586],{"trials":2607,"activeCount":101},[],{"trials":2609,"activeCount":101},[],{"intervention":2611,"totalTrials":134,"cells":2612},"LAF 237",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2629,"NA":2631},{"trials":2614,"activeCount":101},[],{"trials":2616,"activeCount":101},[],{"trials":2618,"activeCount":101},[],{"trials":2620,"activeCount":101},[2621],{"nctId":2622,"briefTitle":2623,"status":111,"phases":2624,"completion":2625,"start":2626,"enrollment":392,"conditions":2627,"interventions":2628},"NCT00230464","Acute Metabolic Effects of LAF 237 in Type 2 Diabetics",[91],"2005-09","2004-11",[188],[2611],{"trials":2630,"activeCount":101},[],{"trials":2632,"activeCount":101},[],{"intervention":2634,"totalTrials":134,"cells":2635},"Nutropin AQ",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2654,"NA":2656},{"trials":2637,"activeCount":101},[],{"trials":2639,"activeCount":101},[],{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":101},[2644],{"nctId":2645,"briefTitle":2646,"status":111,"phases":2647,"primaryCompletion":2648,"completion":2648,"start":2649,"enrollment":351,"conditions":2650,"interventions":2653},"NCT00134420","Growth Hormone and Chromosome 18q- and Abnormal Growth",[91],"2005-06","2001-02",[2651,2652],"Loss of Chromosome 18q","Growth Hormone Deficiency",[2634],{"trials":2655,"activeCount":101},[],{"trials":2657,"activeCount":101},[],{"intervention":2659,"totalTrials":134,"cells":2660},"Enbrel",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2667,"PHASE4":2679,"NA":2681},{"trials":2662,"activeCount":101},[],{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":101},[],{"trials":2668,"activeCount":101},[2669],{"nctId":2670,"briefTitle":2671,"status":1030,"phases":2672,"primaryCompletion":2625,"completion":172,"start":2673,"enrollment":2674,"conditions":2675,"interventions":2678},"NCT00127387","Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia",[90,91],"2001-05",54,[2676,26,2677,1853],"Lung Cancer","Neoplasm Metastasis",[2659],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"intervention":2684,"totalTrials":895,"cells":2685},"Hydroxychloroquine",{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2701,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2687,"activeCount":101},[],{"trials":2689,"activeCount":101},[2690],{"nctId":2691,"briefTitle":2692,"status":111,"phases":2693,"primaryCompletion":2694,"completion":2695,"start":2696,"enrollment":925,"conditions":2697,"interventions":2699},"NCT01023737","Hydroxychloroquine + Vorinostat in Advanced Solid Tumors",[89],"2017-12-05","2023-01-08","2009-11",[2698],"Malignant Solid Tumour",[2684,2700],"Vorinostat",{"trials":2702,"activeCount":101},[2703,2713],{"nctId":2704,"briefTitle":2705,"status":111,"phases":2706,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":952,"conditions":2709,"interventions":2711},"NCT03037437","Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer",[90],"2025-06-27","2017-02-16",[2710],"Hepatocellular Cancer",[2712,2684],"Sorafenib",{"nctId":2714,"briefTitle":2715,"status":111,"phases":2716,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":2379,"conditions":2720,"interventions":2722},"NCT02316340","Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer",[90],"2018-03-07","2018-04-16","2015-02-11",[2721],"Colorectal Cancer",[2700,2684,2723],"Regorafenib",{"trials":2725,"activeCount":101},[],{"trials":2727,"activeCount":101},[],{"trials":2729,"activeCount":101},[],{"intervention":2731,"totalTrials":895,"cells":2732},"Carboplatin",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2748,"PHASE3":2773,"PHASE4":2775,"NA":2777},{"trials":2734,"activeCount":101},[],{"trials":2736,"activeCount":101},[2737],{"nctId":2738,"briefTitle":2739,"status":541,"phases":2740,"primaryCompletion":2741,"completion":2741,"start":2741,"enrollment":101,"conditions":2742,"interventions":2745},"NCT02312804","Ph Ib\u002FBGJ398\u002FCervix and Other Solid Tumors",[89],"2015-01",[2743,2744],"Cancer of Cervix","Tumors",[2746,2731,2747],"BGJ398","Paclitaxel",{"trials":2749,"activeCount":101},[2750,2765],{"nctId":2751,"briefTitle":2752,"status":541,"phases":2753,"primaryCompletion":2754,"completion":2755,"start":2756,"enrollment":101,"conditions":2757,"interventions":2762},"NCT03032614","Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients",[90],"2019-03-31","2020-04-30","2017-09-30",[2758,2759,2760,2761],"Breast Cancer Stage IV","Ovarian Cancer","BRCA1 Mutation","BRCA2 Mutation",[2731,2763,2764],"Eribulin","Veliparib",{"nctId":2766,"briefTitle":2767,"status":541,"phases":2768,"primaryCompletion":2511,"completion":2511,"start":2511,"enrollment":101,"conditions":2769,"interventions":2771},"NCT02396433","Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers",[89,90],[2770],"Cancer of the Breast",[2731,2763,2772],"E7449",{"trials":2774,"activeCount":101},[],{"trials":2776,"activeCount":101},[],{"trials":2778,"activeCount":101},[],{"intervention":2780,"totalTrials":212,"cells":2781},"tipifarnib",{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2795,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2783,"activeCount":101},[],{"trials":2785,"activeCount":101},[2786],{"nctId":2787,"briefTitle":2788,"status":111,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":892,"conditions":2792,"interventions":2793},"NCT00003707","Combination Chemotherapy in Treating Patients With Advanced Cancer",[89],"2002-11","1998-10",[34],[2794,2780],"gemcitabine hydrochloride",{"trials":2796,"activeCount":101},[2797],{"nctId":2798,"briefTitle":2799,"status":541,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":101,"conditions":2803,"interventions":2804},"NCT00054470","Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer",[90],"2003-01","2002-12",[18],[2805,2780],"trastuzumab",{"trials":2807,"activeCount":101},[],{"trials":2809,"activeCount":101},[],{"trials":2811,"activeCount":101},[],{"intervention":2813,"totalTrials":212,"cells":2814},"oblimersen sodium",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2816,"activeCount":101},[],{"trials":2818,"activeCount":101},[],{"trials":2820,"activeCount":101},[2821,2830],{"nctId":2822,"briefTitle":2823,"status":111,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"conditions":2827,"interventions":2828},"NCT00004870","Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer",[89,90],"2002-09","2000-06",[2721],[2813,2829],"irinotecan hydrochloride",{"nctId":2831,"briefTitle":2832,"status":111,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":174,"enrollment":392,"conditions":2835,"interventions":2836},"NCT00055822","Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer",[89,90],"2004-10",[2721],[2813,2837,2838,2839],"fluorouracil","leucovorin calcium","oxaliplatin",{"trials":2841,"activeCount":101},[],{"trials":2843,"activeCount":101},[],{"trials":2845,"activeCount":101},[],{"intervention":2829,"totalTrials":212,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2860,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2849,"activeCount":101},[],{"trials":2851,"activeCount":101},[2852],{"nctId":2853,"briefTitle":2854,"status":111,"phases":2855,"primaryCompletion":2673,"completion":2673,"start":2856,"enrollment":22,"conditions":2857,"interventions":2858},"NCT00003710","Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors",[89],"1998-08",[34],[2829,2859],"mitomycin C",{"trials":2861,"activeCount":101},[2862],{"nctId":2822,"briefTitle":2823,"status":111,"phases":2863,"primaryCompletion":2825,"completion":2825,"start":2826,"conditions":2864,"interventions":2865},[89,90],[2721],[2813,2829],{"trials":2867,"activeCount":101},[],{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"intervention":2873,"totalTrials":212,"cells":2874},"Bevacizumab",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2876,"activeCount":101},[],{"trials":2878,"activeCount":101},[],{"trials":2880,"activeCount":101},[2881,2891],{"nctId":2882,"briefTitle":2883,"status":111,"phases":2884,"primaryCompletion":2885,"completion":2886,"start":2887,"enrollment":1396,"conditions":2888,"interventions":2889},"NCT02342379","TH-302 in Combination With Bevacizumab for Glioblastoma",[90],"2019-01-04","2019-12-04","2015-05",[580],[2873,2890],"TH-302",{"nctId":2892,"briefTitle":2893,"status":111,"phases":2894,"primaryCompletion":2895,"completion":2896,"start":2897,"enrollment":830,"conditions":2898,"interventions":2900},"NCT03032484","TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma",[90],"2020-04-04","2021-04-05","2017-05-18",[2899],"Astrocytoma",[2873,2901],"TVB-2640",{"trials":2903,"activeCount":101},[],{"trials":2905,"activeCount":101},[],{"trials":2907,"activeCount":101},[],{"intervention":2700,"totalTrials":212,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2918,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":101},[2914],{"nctId":2691,"briefTitle":2692,"status":111,"phases":2915,"primaryCompletion":2694,"completion":2695,"start":2696,"enrollment":925,"conditions":2916,"interventions":2917},[89],[2698],[2684,2700],{"trials":2919,"activeCount":101},[2920],{"nctId":2714,"briefTitle":2715,"status":111,"phases":2921,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":2379,"conditions":2922,"interventions":2923},[90],[2721],[2700,2684,2723],{"trials":2925,"activeCount":101},[],{"trials":2927,"activeCount":101},[],{"trials":2929,"activeCount":101},[],{"intervention":2763,"totalTrials":212,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[2938,2942],{"nctId":2751,"briefTitle":2752,"status":541,"phases":2939,"primaryCompletion":2754,"completion":2755,"start":2756,"enrollment":101,"conditions":2940,"interventions":2941},[90],[2758,2759,2760,2761],[2731,2763,2764],{"nctId":2766,"briefTitle":2767,"status":541,"phases":2943,"primaryCompletion":2511,"completion":2511,"start":2511,"enrollment":101,"conditions":2944,"interventions":2945},[89,90],[2770],[2731,2763,2772],{"trials":2947,"activeCount":101},[],{"trials":2949,"activeCount":101},[],{"trials":2951,"activeCount":101},[],{"intervention":2953,"totalTrials":212,"cells":2954},"Eritoran",{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2956,"activeCount":101},[],{"trials":2958,"activeCount":101},[],{"trials":2960,"activeCount":101},[2961,2968],{"nctId":2962,"briefTitle":2963,"status":1030,"phases":2964,"primaryCompletion":516,"completion":516,"start":2741,"enrollment":19,"conditions":2965,"interventions":2966},"NCT02267317","The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects",[90],[1800],[2953,2967],"D5W",{"nctId":2969,"briefTitle":2970,"status":111,"phases":2971,"primaryCompletion":516,"completion":516,"start":2741,"enrollment":97,"conditions":2972,"interventions":2973},"NCT02321111","The Role of TLR4 on Lipid-induced Insulin Resistance",[90],[1800],[2953,2967],{"trials":2975,"activeCount":101},[],{"trials":2977,"activeCount":101},[],{"trials":2979,"activeCount":101},[],{"intervention":2967,"totalTrials":212,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2983,"activeCount":101},[],{"trials":2985,"activeCount":101},[],{"trials":2987,"activeCount":101},[2988,2992],{"nctId":2962,"briefTitle":2963,"status":1030,"phases":2989,"primaryCompletion":516,"completion":516,"start":2741,"enrollment":19,"conditions":2990,"interventions":2991},[90],[1800],[2953,2967],{"nctId":2969,"briefTitle":2970,"status":111,"phases":2993,"primaryCompletion":516,"completion":516,"start":2741,"enrollment":97,"conditions":2994,"interventions":2995},[90],[1800],[2953,2967],{"trials":2997,"activeCount":101},[],{"trials":2999,"activeCount":101},[],{"trials":3001,"activeCount":101},[],{"intervention":3003,"totalTrials":212,"cells":3004},"gefitinib",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":3006,"activeCount":101},[],{"trials":3008,"activeCount":101},[],{"trials":3010,"activeCount":101},[3011,3019],{"nctId":3012,"briefTitle":3013,"status":111,"phases":3014,"primaryCompletion":3015,"completion":3015,"start":3016,"conditions":3017,"interventions":3018},"NCT00030524","ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer",[90],"2003-09","2002-01",[2721],[3003],{"nctId":3020,"briefTitle":3021,"status":111,"phases":3022,"primaryCompletion":3023,"completion":3023,"start":2825,"conditions":3024,"interventions":3025},"NCT00049062","Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer",[90],"2007-10",[18],[3026,3003],"anastrozole",{"trials":3028,"activeCount":101},[],{"trials":3030,"activeCount":101},[],{"trials":3032,"activeCount":101},[],{"intervention":3034,"totalTrials":212,"cells":3035},"Methylene Blue",{"EARLY_PHASE1":3036,"PHASE1":3048,"PHASE2":3050,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3037,"activeCount":101},[3038],{"nctId":3039,"briefTitle":3040,"status":111,"phases":3041,"primaryCompletion":3042,"completion":3042,"start":3043,"enrollment":3044,"conditions":3045,"interventions":3047},"NCT01836094","Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity",[88],"2016-03","2013-08",36,[3046],"Brain Activity",[3034],{"trials":3049,"activeCount":101},[],{"trials":3051,"activeCount":101},[3052],{"nctId":3053,"briefTitle":3054,"status":111,"phases":3055,"primaryCompletion":3056,"completion":3057,"start":1415,"enrollment":3058,"conditions":3059,"interventions":3063},"NCT02380573","Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",[90],"2022-04-21","2023-07",117,[535,3060,24,3061,3062],"MCI","Alzheimer's Disease","AD",[3034,3064,3065],"FD&C Blue # 2","Phenazopyridine hydrochloride",{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"intervention":3073,"totalTrials":212,"cells":3074},"Sevelamer",{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3101,"PHASE4":3103,"NA":3105},{"trials":3076,"activeCount":101},[],{"trials":3078,"activeCount":101},[],{"trials":3080,"activeCount":101},[3081,3092],{"nctId":3082,"briefTitle":3083,"status":111,"phases":3084,"primaryCompletion":3085,"completion":3086,"start":3087,"enrollment":351,"conditions":3088,"interventions":3089},"NCT02124759","Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)",[90],"2018-02-23","2020-03-30","2014-04-02",[1800],[3073,3090,3091],"Synbiotic","Maltodextrin",{"nctId":3093,"briefTitle":3094,"status":111,"phases":3095,"primaryCompletion":516,"completion":3096,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3100},"NCT02127125","Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)",[90],"2018-09-10","2014-04-10",69,[1800],[3091,3090,3073],{"trials":3102,"activeCount":101},[],{"trials":3104,"activeCount":101},[],{"trials":3106,"activeCount":101},[],{"intervention":3090,"totalTrials":212,"cells":3108},{"EARLY_PHASE1":3109,"PHASE1":3111,"PHASE2":3113,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[3115,3119],{"nctId":3082,"briefTitle":3083,"status":111,"phases":3116,"primaryCompletion":3085,"completion":3086,"start":3087,"enrollment":351,"conditions":3117,"interventions":3118},[90],[1800],[3073,3090,3091],{"nctId":3093,"briefTitle":3094,"status":111,"phases":3120,"primaryCompletion":516,"completion":3096,"start":3097,"enrollment":3098,"conditions":3121,"interventions":3122},[90],[1800],[3091,3090,3073],{"trials":3124,"activeCount":101},[],{"trials":3126,"activeCount":101},[],{"trials":3128,"activeCount":101},[],{"intervention":3091,"totalTrials":212,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3132,"activeCount":101},[],{"trials":3134,"activeCount":101},[],{"trials":3136,"activeCount":101},[3137,3141],{"nctId":3082,"briefTitle":3083,"status":111,"phases":3138,"primaryCompletion":3085,"completion":3086,"start":3087,"enrollment":351,"conditions":3139,"interventions":3140},[90],[1800],[3073,3090,3091],{"nctId":3093,"briefTitle":3094,"status":111,"phases":3142,"primaryCompletion":516,"completion":3096,"start":3097,"enrollment":3098,"conditions":3143,"interventions":3144},[90],[1800],[3091,3090,3073],{"trials":3146,"activeCount":101},[],{"trials":3148,"activeCount":101},[],{"trials":3150,"activeCount":101},[],{"intervention":3152,"totalTrials":134,"cells":3153},"Dermaprazole",{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3169,"PHASE4":3171,"NA":3173},{"trials":3155,"activeCount":101},[],{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[3160],{"nctId":3161,"briefTitle":3162,"status":111,"phases":3163,"primaryCompletion":2465,"completion":2465,"start":3164,"enrollment":860,"conditions":3165,"interventions":3167},"NCT04865731","Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer",[90],"2022-06-15",[3166],"Cancer of the Head and Neck",[3152,3168],"Aquaphor",{"trials":3170,"activeCount":101},[],{"trials":3172,"activeCount":101},[],{"trials":3174,"activeCount":101},[],{"intervention":3168,"totalTrials":134,"cells":3176},{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3178,"activeCount":101},[],{"trials":3180,"activeCount":101},[],{"trials":3182,"activeCount":101},[3183],{"nctId":3161,"briefTitle":3162,"status":111,"phases":3184,"primaryCompletion":2465,"completion":2465,"start":3164,"enrollment":860,"conditions":3185,"interventions":3186},[90],[3166],[3152,3168],{"trials":3188,"activeCount":101},[],{"trials":3190,"activeCount":101},[],{"trials":3192,"activeCount":101},[],{"intervention":3194,"totalTrials":134,"cells":3195},"EGFR Antisense DNA",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[3202],{"nctId":3203,"briefTitle":3204,"status":111,"phases":3205,"primaryCompletion":526,"completion":526,"start":3206,"enrollment":860,"conditions":3207,"interventions":3210},"NCT01592721","Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma",[89,90],"2013-04",[3208,3209],"Squamous Cell Carcinoma","Head and Neck Cancer",[3194],{"trials":3212,"activeCount":101},[],{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":101},[],{"intervention":2805,"totalTrials":134,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":101},[3225],{"nctId":2798,"briefTitle":2799,"status":541,"phases":3226,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":101,"conditions":3227,"interventions":3228},[90],[18],[2805,2780],{"trials":3230,"activeCount":101},[],{"trials":3232,"activeCount":101},[],{"trials":3234,"activeCount":101},[],{"intervention":3236,"totalTrials":134,"cells":3237},"Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery",{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3252,"PHASE4":3254,"NA":3256},{"trials":3239,"activeCount":101},[],{"trials":3241,"activeCount":101},[],{"trials":3243,"activeCount":101},[3244],{"nctId":3245,"briefTitle":3246,"status":111,"phases":3247,"primaryCompletion":3248,"completion":3248,"start":141,"enrollment":895,"conditions":3249,"interventions":3251},"NCT01588431","Bevacizumab\u002FPh 2 for Locally Advanced Head and Neck Cancer",[90],"2022-10-04",[3250],"Carcinoma, Squamous Cell of Head and Neck",[3236],{"trials":3253,"activeCount":101},[],{"trials":3255,"activeCount":101},[],{"trials":3257,"activeCount":101},[],{"intervention":3259,"totalTrials":134,"cells":3260},"R-HCVAD and R-MC",{"EARLY_PHASE1":3261,"PHASE1":3263,"PHASE2":3265,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3262,"activeCount":101},[],{"trials":3264,"activeCount":101},[],{"trials":3266,"activeCount":101},[3267],{"nctId":3268,"briefTitle":3269,"status":541,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":101,"conditions":3273,"interventions":3276},"NCT01854372","Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.",[90],"2013-11","2013-06",[3274,3275],"Newly Diagnosed Diffuse Large B-Cell Lymphoma","Intermediate (Burkitt-Like) Lymphoma",[3259],{"trials":3278,"activeCount":101},[],{"trials":3280,"activeCount":101},[],{"trials":3282,"activeCount":101},[],{"intervention":1037,"totalTrials":134,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3286,"activeCount":101},[],{"trials":3288,"activeCount":101},[],{"trials":3290,"activeCount":101},[3291],{"nctId":1028,"briefTitle":1029,"status":1030,"phases":3292,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":3293,"interventions":3294},[90],[26],[1037,1007],{"trials":3296,"activeCount":101},[],{"trials":3298,"activeCount":101},[],{"trials":3300,"activeCount":101},[],{"intervention":2890,"totalTrials":134,"cells":3302},{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3313,"PHASE4":3315,"NA":3317},{"trials":3304,"activeCount":101},[],{"trials":3306,"activeCount":101},[],{"trials":3308,"activeCount":101},[3309],{"nctId":2882,"briefTitle":2883,"status":111,"phases":3310,"primaryCompletion":2885,"completion":2886,"start":2887,"enrollment":1396,"conditions":3311,"interventions":3312},[90],[580],[2873,2890],{"trials":3314,"activeCount":101},[],{"trials":3316,"activeCount":101},[],{"trials":3318,"activeCount":101},[],{"intervention":3320,"totalTrials":134,"cells":3321},"Enteral fish oil",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3323,"activeCount":101},[],{"trials":3325,"activeCount":101},[],{"trials":3327,"activeCount":101},[3328],{"nctId":3329,"briefTitle":3330,"status":541,"phases":3331,"primaryCompletion":517,"completion":517,"start":517,"enrollment":101,"conditions":3332,"interventions":3335},"NCT02420496","Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants",[90],[3333,3334],"Cholestasis","Liver Disease",[3320,3336],"Ursodeoxycholic Acid",{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[],{"intervention":3336,"totalTrials":134,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3346,"activeCount":101},[],{"trials":3348,"activeCount":101},[],{"trials":3350,"activeCount":101},[3351],{"nctId":3329,"briefTitle":3330,"status":541,"phases":3352,"primaryCompletion":517,"completion":517,"start":517,"enrollment":101,"conditions":3353,"interventions":3354},[90],[3333,3334],[3320,3336],{"trials":3356,"activeCount":101},[],{"trials":3358,"activeCount":101},[],{"trials":3360,"activeCount":101},[],{"intervention":3362,"totalTrials":134,"cells":3363},"Arsenic Trioxide",{"EARLY_PHASE1":3364,"PHASE1":3366,"PHASE2":3368,"PHASE3":3379,"PHASE4":3381,"NA":3383},{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[],{"trials":3369,"activeCount":101},[3370],{"nctId":3371,"briefTitle":3372,"status":111,"phases":3373,"primaryCompletion":3374,"completion":3374,"start":979,"enrollment":3375,"conditions":3376,"interventions":3378},"NCT01428128","Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector",[90],"2013-01",50,[3377],"Cancer Other Than Leukemia",[3362],{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"trials":3384,"activeCount":101},[],{"intervention":3386,"totalTrials":134,"cells":3387},"Epidiolex 100 mg\u002FmL Oral Solution",{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3405,"PHASE4":3407,"NA":3409},{"trials":3389,"activeCount":101},[],{"trials":3391,"activeCount":101},[],{"trials":3393,"activeCount":101},[3394],{"nctId":3395,"briefTitle":3396,"status":111,"phases":3397,"primaryCompletion":3398,"completion":3399,"start":3400,"enrollment":952,"conditions":3401,"interventions":3404},"NCT04642404","CBD for Dental Pain",[89,90],"2023-03-02","2023-03-13","2021-03-01",[3402,3403],"Odontalgia","Toothache",[3386],{"trials":3406,"activeCount":101},[],{"trials":3408,"activeCount":101},[],{"trials":3410,"activeCount":101},[],{"intervention":2837,"totalTrials":134,"cells":3412},{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3417,"PHASE3":3423,"PHASE4":3425,"NA":3427},{"trials":3414,"activeCount":101},[],{"trials":3416,"activeCount":101},[],{"trials":3418,"activeCount":101},[3419],{"nctId":2831,"briefTitle":2832,"status":111,"phases":3420,"primaryCompletion":2834,"completion":2834,"start":174,"enrollment":392,"conditions":3421,"interventions":3422},[89,90],[2721],[2813,2837,2838,2839],{"trials":3424,"activeCount":101},[],{"trials":3426,"activeCount":101},[],{"trials":3428,"activeCount":101},[],{"intervention":2838,"totalTrials":134,"cells":3430},{"EARLY_PHASE1":3431,"PHASE1":3433,"PHASE2":3435,"PHASE3":3441,"PHASE4":3443,"NA":3445},{"trials":3432,"activeCount":101},[],{"trials":3434,"activeCount":101},[],{"trials":3436,"activeCount":101},[3437],{"nctId":2831,"briefTitle":2832,"status":111,"phases":3438,"primaryCompletion":2834,"completion":2834,"start":174,"enrollment":392,"conditions":3439,"interventions":3440},[89,90],[2721],[2813,2837,2838,2839],{"trials":3442,"activeCount":101},[],{"trials":3444,"activeCount":101},[],{"trials":3446,"activeCount":101},[],{"intervention":2839,"totalTrials":134,"cells":3448},{"EARLY_PHASE1":3449,"PHASE1":3451,"PHASE2":3453,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3450,"activeCount":101},[],{"trials":3452,"activeCount":101},[],{"trials":3454,"activeCount":101},[3455],{"nctId":2831,"briefTitle":2832,"status":111,"phases":3456,"primaryCompletion":2834,"completion":2834,"start":174,"enrollment":392,"conditions":3457,"interventions":3458},[89,90],[2721],[2813,2837,2838,2839],{"trials":3460,"activeCount":101},[],{"trials":3462,"activeCount":101},[],{"trials":3464,"activeCount":101},[],{"intervention":2712,"totalTrials":134,"cells":3466},{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3468,"activeCount":101},[],{"trials":3470,"activeCount":101},[],{"trials":3472,"activeCount":101},[3473],{"nctId":2704,"briefTitle":2705,"status":111,"phases":3474,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":952,"conditions":3475,"interventions":3476},[90],[2710],[2712,2684],{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[],{"intervention":3484,"totalTrials":134,"cells":3485},"Dasatinib + Quercetin",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3487,"activeCount":101},[],{"trials":3489,"activeCount":101},[],{"trials":3491,"activeCount":101},[3492],{"nctId":3493,"briefTitle":3494,"status":111,"phases":3495,"primaryCompletion":3496,"completion":922,"start":3497,"enrollment":3498,"conditions":3499,"interventions":3500},"NCT04063124","Senolytic Therapy to Modulate Progression of Alzheimer's Disease",[89,90],"2021-12-10","2020-02-14",5,[536],[3484],{"trials":3502,"activeCount":101},[],{"trials":3504,"activeCount":101},[],{"trials":3506,"activeCount":101},[],{"intervention":3508,"totalTrials":134,"cells":3509},"Esketamine",{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3514,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3511,"activeCount":101},[],{"trials":3513,"activeCount":101},[],{"trials":3515,"activeCount":101},[3516],{"nctId":3517,"briefTitle":3518,"status":111,"phases":3519,"primaryCompletion":3520,"completion":3520,"start":3521,"enrollment":1885,"conditions":3522,"interventions":3524},"NCT06795659","Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)",[89,90],"2026-01-16","2025-06-09",[3523],"Post Traumatic Stress Disorder PTSD",[3508],{"trials":3526,"activeCount":101},[],{"trials":3528,"activeCount":101},[],{"trials":3530,"activeCount":101},[],{"intervention":2723,"totalTrials":134,"cells":3532},{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3543,"PHASE4":3545,"NA":3547},{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[3539],{"nctId":2714,"briefTitle":2715,"status":111,"phases":3540,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":2379,"conditions":3541,"interventions":3542},[90],[2721],[2700,2684,2723],{"trials":3544,"activeCount":101},[],{"trials":3546,"activeCount":101},[],{"trials":3548,"activeCount":101},[],{"intervention":3550,"totalTrials":134,"cells":3551},"Nexrutine",{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3553,"activeCount":101},[],{"trials":3555,"activeCount":101},[],{"trials":3557,"activeCount":101},[3558],{"nctId":3559,"briefTitle":3560,"status":1030,"phases":3561,"primaryCompletion":3562,"completion":3562,"start":3563,"enrollment":1034,"conditions":3564,"interventions":3565},"NCT01705652","Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients",[90],"2014-03","2011-07",[26],[3550],{"trials":3567,"activeCount":101},[],{"trials":3569,"activeCount":101},[],{"trials":3571,"activeCount":101},[],{"intervention":2901,"totalTrials":134,"cells":3573},{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3584,"PHASE4":3586,"NA":3588},{"trials":3575,"activeCount":101},[],{"trials":3577,"activeCount":101},[],{"trials":3579,"activeCount":101},[3580],{"nctId":2892,"briefTitle":2893,"status":111,"phases":3581,"primaryCompletion":2895,"completion":2896,"start":2897,"enrollment":830,"conditions":3582,"interventions":3583},[90],[2899],[2873,2901],{"trials":3585,"activeCount":101},[],{"trials":3587,"activeCount":101},[],{"trials":3589,"activeCount":101},[],{"intervention":3591,"totalTrials":134,"cells":3592},"TH-302 preoperative",{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3594,"activeCount":101},[],{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":101},[3599],{"nctId":3600,"briefTitle":3601,"status":111,"phases":3602,"primaryCompletion":2159,"completion":2159,"start":248,"enrollment":1493,"conditions":3603,"interventions":3605},"NCT01403610","Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab",[90],[3604],"HIGH GRADE GLIOMA",[3591,3606],"TH-302 (escalating) with bevacizumab 10mg\u002Fkg",{"trials":3608,"activeCount":101},[],{"trials":3610,"activeCount":101},[],{"trials":3612,"activeCount":101},[],{"intervention":3606,"totalTrials":134,"cells":3614},{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3619,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3616,"activeCount":101},[],{"trials":3618,"activeCount":101},[],{"trials":3620,"activeCount":101},[3621],{"nctId":3600,"briefTitle":3601,"status":111,"phases":3622,"primaryCompletion":2159,"completion":2159,"start":248,"enrollment":1493,"conditions":3623,"interventions":3624},[90],[3604],[3591,3606],{"trials":3626,"activeCount":101},[],{"trials":3628,"activeCount":101},[],{"trials":3630,"activeCount":101},[],{"intervention":2764,"totalTrials":134,"cells":3632},{"EARLY_PHASE1":3633,"PHASE1":3635,"PHASE2":3637,"PHASE3":3643,"PHASE4":3645,"NA":3647},{"trials":3634,"activeCount":101},[],{"trials":3636,"activeCount":101},[],{"trials":3638,"activeCount":101},[3639],{"nctId":2751,"briefTitle":2752,"status":541,"phases":3640,"primaryCompletion":2754,"completion":2755,"start":2756,"enrollment":101,"conditions":3641,"interventions":3642},[90],[2758,2759,2760,2761],[2731,2763,2764],{"trials":3644,"activeCount":101},[],{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":101},[],{"intervention":3650,"totalTrials":134,"cells":3651},"Ontak",{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3656,"PHASE3":3669,"PHASE4":3671,"NA":3673},{"trials":3653,"activeCount":101},[],{"trials":3655,"activeCount":101},[],{"trials":3657,"activeCount":101},[3658],{"nctId":3659,"briefTitle":3660,"status":111,"phases":3661,"primaryCompletion":113,"completion":113,"start":3662,"enrollment":3663,"conditions":3664,"interventions":3668},"NCT00880360","A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer",[90],"2007-02",19,[3665,3666,3667],"Epithelial Ovarian Cancer","Extraovarian Peritoneal Cancer","Fallopian Tube Carcinoma",[3650],{"trials":3670,"activeCount":101},[],{"trials":3672,"activeCount":101},[],{"trials":3674,"activeCount":101},[],{"intervention":2772,"totalTrials":134,"cells":3676},{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3678,"activeCount":101},[],{"trials":3680,"activeCount":101},[],{"trials":3682,"activeCount":101},[3683],{"nctId":2766,"briefTitle":2767,"status":541,"phases":3684,"primaryCompletion":2511,"completion":2511,"start":2511,"enrollment":101,"conditions":3685,"interventions":3686},[89,90],[2770],[2731,2763,2772],{"trials":3688,"activeCount":101},[],{"trials":3690,"activeCount":101},[],{"trials":3692,"activeCount":101},[],{"intervention":3694,"totalTrials":134,"cells":3695},"irofulven",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3711,"PHASE4":3713,"NA":3715},{"trials":3697,"activeCount":101},[],{"trials":3699,"activeCount":101},[],{"trials":3701,"activeCount":101},[3702],{"nctId":3703,"briefTitle":3704,"status":111,"phases":3705,"primaryCompletion":3706,"completion":3706,"start":3707,"enrollment":895,"conditions":3708,"interventions":3710},"NCT00003760","Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer",[90],"2000-05","1998-11",[3709],"Pancreatic Cancer",[3694],{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[],{"intervention":3026,"totalTrials":134,"cells":3718},{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3723,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3720,"activeCount":101},[],{"trials":3722,"activeCount":101},[],{"trials":3724,"activeCount":101},[3725],{"nctId":3020,"briefTitle":3021,"status":111,"phases":3726,"primaryCompletion":3023,"completion":3023,"start":2825,"conditions":3727,"interventions":3728},[90],[18],[3026,3003],{"trials":3730,"activeCount":101},[],{"trials":3732,"activeCount":101},[],{"trials":3734,"activeCount":101},[],{"intervention":3736,"totalTrials":134,"cells":3737},"Control toothpaste containing Novamin® technology",{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3742,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3739,"activeCount":101},[],{"trials":3741,"activeCount":101},[],{"trials":3743,"activeCount":101},[3744],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3747,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3749,"interventions":3751},"NCT02918617","Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream",[90],203,[3750],"Dentin Sensitivity",[3736,3752,3753,3753,3754,3755,3753,3756,3757],"Control toothpaste containing 1500 ppm fluoride as MFP","Test toothpaste with nano-HAP","Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3","Control toothpaste without nano-HAP","Test cream with nano-HAP","Control cream without nano-HAP",{"trials":3759,"activeCount":101},[],{"trials":3761,"activeCount":101},[],{"trials":3763,"activeCount":101},[],{"intervention":3752,"totalTrials":134,"cells":3765},{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3770,"PHASE3":3776,"PHASE4":3778,"NA":3780},{"trials":3767,"activeCount":101},[],{"trials":3769,"activeCount":101},[],{"trials":3771,"activeCount":101},[3772],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3773,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3774,"interventions":3775},[90],[3750],[3736,3752,3753,3753,3754,3755,3753,3756,3757],{"trials":3777,"activeCount":101},[],{"trials":3779,"activeCount":101},[],{"trials":3781,"activeCount":101},[],{"intervention":3753,"totalTrials":134,"cells":3783},{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3794,"PHASE4":3796,"NA":3798},{"trials":3785,"activeCount":101},[],{"trials":3787,"activeCount":101},[],{"trials":3789,"activeCount":101},[3790],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3791,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3792,"interventions":3793},[90],[3750],[3736,3752,3753,3753,3754,3755,3753,3756,3757],{"trials":3795,"activeCount":101},[],{"trials":3797,"activeCount":101},[],{"trials":3799,"activeCount":101},[],{"intervention":3754,"totalTrials":134,"cells":3801},{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3803,"activeCount":101},[],{"trials":3805,"activeCount":101},[],{"trials":3807,"activeCount":101},[3808],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3809,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3810,"interventions":3811},[90],[3750],[3736,3752,3753,3753,3754,3755,3753,3756,3757],{"trials":3813,"activeCount":101},[],{"trials":3815,"activeCount":101},[],{"trials":3817,"activeCount":101},[],{"intervention":3755,"totalTrials":134,"cells":3819},{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3821,"activeCount":101},[],{"trials":3823,"activeCount":101},[],{"trials":3825,"activeCount":101},[3826],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3827,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3828,"interventions":3829},[90],[3750],[3736,3752,3753,3753,3754,3755,3753,3756,3757],{"trials":3831,"activeCount":101},[],{"trials":3833,"activeCount":101},[],{"trials":3835,"activeCount":101},[],{"intervention":3756,"totalTrials":134,"cells":3837},{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3842,"PHASE3":3848,"PHASE4":3850,"NA":3852},{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":101},[],{"trials":3843,"activeCount":101},[3844],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3845,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3846,"interventions":3847},[90],[3750],[3736,3752,3753,3753,3754,3755,3753,3756,3757],{"trials":3849,"activeCount":101},[],{"trials":3851,"activeCount":101},[],{"trials":3853,"activeCount":101},[],{"intervention":3757,"totalTrials":134,"cells":3855},{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3866,"PHASE4":3868,"NA":3870},{"trials":3857,"activeCount":101},[],{"trials":3859,"activeCount":101},[],{"trials":3861,"activeCount":101},[3862],{"nctId":3745,"briefTitle":3746,"status":111,"phases":3863,"primaryCompletion":978,"completion":978,"start":2887,"enrollment":3748,"conditions":3864,"interventions":3865},[90],[3750],[3736,3752,3753,3753,3754,3755,3753,3756,3757],{"trials":3867,"activeCount":101},[],{"trials":3869,"activeCount":101},[],{"trials":3871,"activeCount":101},[],{"intervention":3873,"totalTrials":134,"cells":3874},"3TC",{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3891,"PHASE4":3893,"NA":3895},{"trials":3876,"activeCount":101},[],{"trials":3878,"activeCount":101},[],{"trials":3880,"activeCount":101},[3881],{"nctId":3882,"briefTitle":3883,"status":111,"phases":3884,"primaryCompletion":3885,"completion":3886,"start":3887,"enrollment":22,"conditions":3888,"interventions":3890},"NCT04552795","Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease",[89,90],"2023-05-04","2023-11-04","2021-02-15",[3889],"Alzheimer Disease, Early Onset",[3873],{"trials":3892,"activeCount":101},[],{"trials":3894,"activeCount":101},[],{"trials":3896,"activeCount":101},[],{"intervention":3898,"totalTrials":134,"cells":3899},"ORMD-0801 capsules- 2x8mg",{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3901,"activeCount":101},[],{"trials":3903,"activeCount":101},[],{"trials":3905,"activeCount":101},[3906],{"nctId":3907,"briefTitle":3908,"status":111,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":2741,"enrollment":27,"conditions":3911,"interventions":3913},"NCT02535715","A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)",[90],"2017-04",[3912],"Type 1 Diabetes",[3898,3914,3915],"ORMD-0801 capsules- 3x8mg","ORMD-0801 capsules- 1x16mg",{"trials":3917,"activeCount":101},[],{"trials":3919,"activeCount":101},[],{"trials":3921,"activeCount":101},[],{"intervention":3914,"totalTrials":134,"cells":3923},{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3925,"activeCount":101},[],{"trials":3927,"activeCount":101},[],{"trials":3929,"activeCount":101},[3930],{"nctId":3907,"briefTitle":3908,"status":111,"phases":3931,"primaryCompletion":3910,"completion":3910,"start":2741,"enrollment":27,"conditions":3932,"interventions":3933},[90],[3912],[3898,3914,3915],{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[],{"trials":3939,"activeCount":101},[],{"intervention":3915,"totalTrials":134,"cells":3941},{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3946,"PHASE3":3952,"PHASE4":3954,"NA":3956},{"trials":3943,"activeCount":101},[],{"trials":3945,"activeCount":101},[],{"trials":3947,"activeCount":101},[3948],{"nctId":3907,"briefTitle":3908,"status":111,"phases":3949,"primaryCompletion":3910,"completion":3910,"start":2741,"enrollment":27,"conditions":3950,"interventions":3951},[90],[3912],[3898,3914,3915],{"trials":3953,"activeCount":101},[],{"trials":3955,"activeCount":101},[],{"trials":3957,"activeCount":101},[],{"intervention":3959,"totalTrials":134,"cells":3960},"bemcentinib",{"EARLY_PHASE1":3961,"PHASE1":3963,"PHASE2":3965,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3962,"activeCount":101},[],{"trials":3964,"activeCount":101},[],{"trials":3966,"activeCount":101},[3967],{"nctId":3968,"briefTitle":3969,"status":1030,"phases":3970,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":1885,"conditions":3973,"interventions":3975},"NCT06516887","Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma",[89,90],"2026-05-21","2024-12-27",[3974],"Advanced Lung Adenocarcinoma",[3959,3976],"pacritinib",{"trials":3978,"activeCount":101},[],{"trials":3980,"activeCount":101},[],{"trials":3982,"activeCount":101},[],{"intervention":3976,"totalTrials":134,"cells":3984},{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3995,"PHASE4":3997,"NA":3999},{"trials":3986,"activeCount":101},[],{"trials":3988,"activeCount":101},[],{"trials":3990,"activeCount":101},[3991],{"nctId":3968,"briefTitle":3969,"status":1030,"phases":3992,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":1885,"conditions":3993,"interventions":3994},[89,90],[3974],[3959,3976],{"trials":3996,"activeCount":101},[],{"trials":3998,"activeCount":101},[],{"trials":4000,"activeCount":101},[],{"intervention":4002,"totalTrials":134,"cells":4003},"Nicotinamide riboside",{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[4010],{"nctId":4011,"briefTitle":4012,"status":111,"phases":4013,"primaryCompletion":4014,"completion":4015,"start":4016,"enrollment":1493,"conditions":4017,"interventions":4020},"NCT04818216","Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection",[90],"2021-12-09","2022-01-03","2021-06-11",[4018,4019],"SARS-CoV-2 Infection","Acute Kidney Injury",[4002],{"trials":4022,"activeCount":101},[],{"trials":4024,"activeCount":101},[],{"trials":4026,"activeCount":101},[],{"intervention":4028,"totalTrials":134,"cells":4029},"Denileukin Diftitox\u002FSC Pegylated IFNα-2a",{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4043,"PHASE4":4045,"NA":4047},{"trials":4031,"activeCount":101},[],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[4036],{"nctId":4037,"briefTitle":4038,"status":1030,"phases":4039,"primaryCompletion":248,"completion":248,"start":4040,"enrollment":212,"conditions":4041,"interventions":4042},"NCT01773889","A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer",[90],"2009-06",[3665,3666,3667],[4028],{"trials":4044,"activeCount":101},[],{"trials":4046,"activeCount":101},[],{"trials":4048,"activeCount":101},[],{"intervention":4050,"totalTrials":134,"cells":4051},"Cannabidiol (CBD) oral solution",{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4056,"PHASE3":4067,"PHASE4":4069,"NA":4071},{"trials":4053,"activeCount":101},[],{"trials":4055,"activeCount":101},[],{"trials":4057,"activeCount":101},[4058],{"nctId":4059,"briefTitle":4060,"status":111,"phases":4061,"primaryCompletion":4062,"completion":4062,"start":4063,"enrollment":1034,"conditions":4064,"interventions":4066},"NCT05132699","Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder",[89,90],"2023-06-30","2022-04-04",[4065,614],"Posttraumatic Stress Disorder",[4050],{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[],{"trials":4072,"activeCount":101},[],{"intervention":4074,"totalTrials":134,"cells":4075},"OSI-774",{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4091,"PHASE4":4093,"NA":4095},{"trials":4077,"activeCount":101},[],{"trials":4079,"activeCount":101},[],{"trials":4081,"activeCount":101},[4082],{"nctId":4083,"briefTitle":4084,"status":111,"phases":4085,"primaryCompletion":4086,"completion":4086,"start":4087,"enrollment":980,"conditions":4088,"interventions":4090},"NCT00045487","Erlotinib in Treating Patients With Advanced Kidney Cancer",[90],"2008-05","2002-06",[4089],"Kidney Cancer",[4074],{"trials":4092,"activeCount":101},[],{"trials":4094,"activeCount":101},[],{"trials":4096,"activeCount":101},[],{"intervention":4098,"totalTrials":134,"cells":4099},"AGEN1884",{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4119,"PHASE4":4121,"NA":4123},{"trials":4101,"activeCount":101},[],{"trials":4103,"activeCount":101},[],{"trials":4105,"activeCount":101},[4106],{"nctId":4107,"briefTitle":4108,"status":1030,"phases":4109,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":1885,"conditions":4113,"interventions":4115},"NCT04430036","AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer",[90],"2021-10-18","2022-03-14","2020-10-14",[4114],"Urinary Bladder Neoplasms",[4098,4116,4117,4118],"AGEN2034","Cisplatin","Gemcitabine",{"trials":4120,"activeCount":101},[],{"trials":4122,"activeCount":101},[],{"trials":4124,"activeCount":101},[],{"intervention":4116,"totalTrials":134,"cells":4126},{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4137,"PHASE4":4139,"NA":4141},{"trials":4128,"activeCount":101},[],{"trials":4130,"activeCount":101},[],{"trials":4132,"activeCount":101},[4133],{"nctId":4107,"briefTitle":4108,"status":1030,"phases":4134,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":1885,"conditions":4135,"interventions":4136},[90],[4114],[4098,4116,4117,4118],{"trials":4138,"activeCount":101},[],{"trials":4140,"activeCount":101},[],{"trials":4142,"activeCount":101},[],{"intervention":4117,"totalTrials":134,"cells":4144},{"EARLY_PHASE1":4145,"PHASE1":4147,"PHASE2":4149,"PHASE3":4155,"PHASE4":4157,"NA":4159},{"trials":4146,"activeCount":101},[],{"trials":4148,"activeCount":101},[],{"trials":4150,"activeCount":101},[4151],{"nctId":4107,"briefTitle":4108,"status":1030,"phases":4152,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":1885,"conditions":4153,"interventions":4154},[90],[4114],[4098,4116,4117,4118],{"trials":4156,"activeCount":101},[],{"trials":4158,"activeCount":101},[],{"trials":4160,"activeCount":101},[],{"intervention":4118,"totalTrials":134,"cells":4162},{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4173,"PHASE4":4175,"NA":4177},{"trials":4164,"activeCount":101},[],{"trials":4166,"activeCount":101},[],{"trials":4168,"activeCount":101},[4169],{"nctId":4107,"briefTitle":4108,"status":1030,"phases":4170,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":1885,"conditions":4171,"interventions":4172},[90],[4114],[4098,4116,4117,4118],{"trials":4174,"activeCount":101},[],{"trials":4176,"activeCount":101},[],{"trials":4178,"activeCount":101},[],{"intervention":4180,"totalTrials":134,"cells":4181},"Dapagliflozin 10 mg",{"EARLY_PHASE1":4182,"PHASE1":4184,"PHASE2":4186,"PHASE3":4196,"PHASE4":4198,"NA":4200},{"trials":4183,"activeCount":101},[],{"trials":4185,"activeCount":101},[],{"trials":4187,"activeCount":101},[4188],{"nctId":4189,"briefTitle":4190,"status":111,"phases":4191,"primaryCompletion":4192,"completion":4192,"start":4193,"enrollment":351,"conditions":4194,"interventions":4195},"NCT04401904","SGLT2 Inhibition in Older Obese Adults With Pre-diabetes",[89,90],"2022-09-14","2020-06-25",[24],[4180],{"trials":4197,"activeCount":101},[],{"trials":4199,"activeCount":101},[],{"trials":4201,"activeCount":101},[],{"intervention":3064,"totalTrials":134,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4214,"PHASE4":4216,"NA":4218},{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[4210],{"nctId":3053,"briefTitle":3054,"status":111,"phases":4211,"primaryCompletion":3056,"completion":3057,"start":1415,"enrollment":3058,"conditions":4212,"interventions":4213},[90],[535,3060,24,3061,3062],[3034,3064,3065],{"trials":4215,"activeCount":101},[],{"trials":4217,"activeCount":101},[],{"trials":4219,"activeCount":101},[],{"intervention":3065,"totalTrials":134,"cells":4221},{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4232,"PHASE4":4234,"NA":4236},{"trials":4223,"activeCount":101},[],{"trials":4225,"activeCount":101},[],{"trials":4227,"activeCount":101},[4228],{"nctId":3053,"briefTitle":3054,"status":111,"phases":4229,"primaryCompletion":3056,"completion":3057,"start":1415,"enrollment":3058,"conditions":4230,"interventions":4231},[90],[535,3060,24,3061,3062],[3034,3064,3065],{"trials":4233,"activeCount":101},[],{"trials":4235,"activeCount":101},[],{"trials":4237,"activeCount":101},[],{"intervention":4239,"totalTrials":134,"cells":4240},"acarbose",{"EARLY_PHASE1":4241,"PHASE1":4243,"PHASE2":4245,"PHASE3":4254,"PHASE4":4256,"NA":4258},{"trials":4242,"activeCount":101},[],{"trials":4244,"activeCount":101},[],{"trials":4246,"activeCount":101},[4247],{"nctId":4248,"briefTitle":4249,"status":111,"phases":4250,"primaryCompletion":4251,"completion":4251,"start":517,"enrollment":35,"conditions":4252,"interventions":4253},"NCT02865499","Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)",[90],"2017-10",[24],[4239],{"trials":4255,"activeCount":101},[],{"trials":4257,"activeCount":101},[],{"trials":4259,"activeCount":101},[],{"intervention":4261,"totalTrials":212,"cells":4262},"Mitomycin C",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4279,"PHASE3":4281,"PHASE4":4283,"NA":4285},{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[4267,4275],{"nctId":4268,"briefTitle":4269,"status":111,"phases":4270,"primaryCompletion":2511,"completion":2511,"start":4271,"enrollment":16,"conditions":4272,"interventions":4274},"NCT02311101","Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer",[89],"2012-03",[4273],"Urinary Bladder Neoplasm",[4261],{"nctId":2853,"briefTitle":2854,"status":111,"phases":4276,"primaryCompletion":2673,"completion":2673,"start":2856,"enrollment":22,"conditions":4277,"interventions":4278},[89],[34],[2829,2859],{"trials":4280,"activeCount":101},[],{"trials":4282,"activeCount":101},[],{"trials":4284,"activeCount":101},[],{"trials":4286,"activeCount":101},[],{"intervention":4288,"totalTrials":134,"cells":4289},"R-Chop and Roflumilast",{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4303,"PHASE3":4305,"PHASE4":4307,"NA":4309},{"trials":4291,"activeCount":101},[],{"trials":4293,"activeCount":101},[4294],{"nctId":4295,"briefTitle":4296,"status":541,"phases":4297,"primaryCompletion":4298,"completion":4299,"start":4300,"enrollment":101,"conditions":4301,"interventions":4302},"NCT05796271","Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy",[89],"2027-01","2028-01","2024-01",[1059],[4288],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"trials":4310,"activeCount":101},[],{"intervention":4312,"totalTrials":134,"cells":4313},"bizelesin",{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4325,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[4318],{"nctId":4319,"briefTitle":4320,"status":111,"phases":4321,"primaryCompletion":2790,"completion":2790,"start":4322,"conditions":4323,"interventions":4324},"NCT00003021","Bizelesin in Treating Patients With Advanced Cancer",[89],"1997-08",[34],[4312],{"trials":4326,"activeCount":101},[],{"trials":4328,"activeCount":101},[],{"trials":4330,"activeCount":101},[],{"trials":4332,"activeCount":101},[],{"intervention":4334,"totalTrials":134,"cells":4335},"ɛ-Aminocaproic Acid",{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4349,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4337,"activeCount":101},[],{"trials":4339,"activeCount":101},[4340],{"nctId":4341,"briefTitle":4342,"status":541,"phases":4343,"primaryCompletion":4344,"completion":4345,"start":517,"enrollment":101,"conditions":4346,"interventions":4348},"NCT02639819","Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study",[89],"2017-07","2017-12",[4347],"Intracerebral Hemorrhage",[4334],{"trials":4350,"activeCount":101},[],{"trials":4352,"activeCount":101},[],{"trials":4354,"activeCount":101},[],{"trials":4356,"activeCount":101},[],{"intervention":4358,"totalTrials":134,"cells":4359},"Sorafenib combined with Hydroxychloroquine",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4371,"PHASE3":4373,"PHASE4":4375,"NA":4377},{"trials":4361,"activeCount":101},[],{"trials":4363,"activeCount":101},[4364],{"nctId":4365,"briefTitle":4366,"status":111,"phases":4367,"primaryCompletion":2440,"completion":2440,"start":389,"enrollment":16,"conditions":4368,"interventions":4370},"NCT01634893","Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors",[89],[4369],"Refractory or Relapsed Solid Tumors",[4358],{"trials":4372,"activeCount":101},[],{"trials":4374,"activeCount":101},[],{"trials":4376,"activeCount":101},[],{"trials":4378,"activeCount":101},[],{"intervention":4380,"totalTrials":134,"cells":4381},"bexmarilimab",{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4396,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4383,"activeCount":101},[],{"trials":4385,"activeCount":101},[4386],{"nctId":4387,"briefTitle":4388,"status":541,"phases":4389,"primaryCompletion":4390,"completion":219,"start":4391,"enrollment":101,"conditions":4392,"interventions":4394},"NCT05171062","Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer",[89],"2025-12","2023-06",[4393],"Non-small Cell Lung Cancer",[4380,4395],"Pembrolizumab",{"trials":4397,"activeCount":101},[],{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":101},[],{"trials":4403,"activeCount":101},[],{"intervention":4395,"totalTrials":134,"cells":4405},{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4414,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[4410],{"nctId":4387,"briefTitle":4388,"status":541,"phases":4411,"primaryCompletion":4390,"completion":219,"start":4391,"enrollment":101,"conditions":4412,"interventions":4413},[89],[4393],[4380,4395],{"trials":4415,"activeCount":101},[],{"trials":4417,"activeCount":101},[],{"trials":4419,"activeCount":101},[],{"trials":4421,"activeCount":101},[],{"intervention":4423,"totalTrials":134,"cells":4424},"carbendazim",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4442},{"trials":4426,"activeCount":101},[],{"trials":4428,"activeCount":101},[4429],{"nctId":4430,"briefTitle":4431,"status":111,"phases":4432,"primaryCompletion":4433,"completion":4433,"start":2791,"enrollment":830,"conditions":4434,"interventions":4435},"NCT00003709","Chemotherapy in Treating Patients With Advanced Solid Tumors",[89],"2000-11",[34],[4423],{"trials":4437,"activeCount":101},[],{"trials":4439,"activeCount":101},[],{"trials":4441,"activeCount":101},[],{"trials":4443,"activeCount":101},[],{"intervention":4445,"totalTrials":134,"cells":4446},"Beta-hydroxy-butyrate",{"EARLY_PHASE1":4447,"PHASE1":4449,"PHASE2":4460,"PHASE3":4462,"PHASE4":4464,"NA":4466},{"trials":4448,"activeCount":101},[],{"trials":4450,"activeCount":101},[4451],{"nctId":4452,"briefTitle":4453,"status":111,"phases":4454,"primaryCompletion":4455,"completion":4456,"start":4457,"enrollment":980,"conditions":4458,"interventions":4459},"NCT03560323","Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1",[89],"2024-08-30","2024-12-30","2019-01-07",[2162,188],[4445],{"trials":4461,"activeCount":101},[],{"trials":4463,"activeCount":101},[],{"trials":4465,"activeCount":101},[],{"trials":4467,"activeCount":101},[],{"intervention":4469,"totalTrials":134,"cells":4470},"SP-420",{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4484,"PHASE3":4486,"PHASE4":4488,"NA":4490},{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":101},[4475],{"nctId":4476,"briefTitle":4477,"status":1030,"phases":4478,"primaryCompletion":4479,"completion":4479,"start":4480,"enrollment":212,"conditions":4481,"interventions":4483},"NCT04741542","Safety of SP-420 in the Treatment of Transfusional Iron Overload",[89],"2024-01-10","2021-03-09",[4482],"Iron Overload",[4469],{"trials":4485,"activeCount":101},[],{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"trials":4491,"activeCount":101},[],{"intervention":4493,"totalTrials":134,"cells":4494},"incyclinide",{"EARLY_PHASE1":4495,"PHASE1":4497,"PHASE2":4506,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4496,"activeCount":101},[],{"trials":4498,"activeCount":101},[4499],{"nctId":4500,"briefTitle":4431,"status":111,"phases":4501,"primaryCompletion":4502,"completion":4502,"start":3707,"enrollment":4503,"conditions":4504,"interventions":4505},"NCT00003721",[89],"2002-04",33,[34],[4493],{"trials":4507,"activeCount":101},[],{"trials":4509,"activeCount":101},[],{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"intervention":4515,"totalTrials":134,"cells":4516},"temozolomide",{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4527,"PHASE3":4529,"PHASE4":4531,"NA":4533},{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":101},[4521],{"nctId":4522,"briefTitle":4431,"status":111,"phases":4523,"primaryCompletion":3706,"completion":3706,"start":4524,"enrollment":592,"conditions":4525,"interventions":4526},"NCT00003708",[89],"1998-07",[34],[4515],{"trials":4528,"activeCount":101},[],{"trials":4530,"activeCount":101},[],{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"intervention":4536,"totalTrials":134,"cells":4537},"ridaforolimus",{"EARLY_PHASE1":4538,"PHASE1":4540,"PHASE2":4549,"PHASE3":4551,"PHASE4":4553,"NA":4555},{"trials":4539,"activeCount":101},[],{"trials":4541,"activeCount":101},[4542],{"nctId":4543,"briefTitle":4544,"status":541,"phases":4545,"primaryCompletion":2353,"completion":2353,"start":2033,"enrollment":101,"conditions":4546,"interventions":4548},"NCT01296659","Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma",[89],[4547],"Soft Tissue Sarcoma",[4536],{"trials":4550,"activeCount":101},[],{"trials":4552,"activeCount":101},[],{"trials":4554,"activeCount":101},[],{"trials":4556,"activeCount":101},[],{"intervention":4558,"totalTrials":134,"cells":4559},"temsirolimus",{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4561,"activeCount":101},[],{"trials":4563,"activeCount":101},[4564],{"nctId":4565,"briefTitle":4566,"status":111,"phases":4567,"primaryCompletion":4087,"completion":4087,"start":4568,"enrollment":19,"conditions":4569,"interventions":4572},"NCT00003712","CCI-779 in Treating Patients With Advanced Solid Tumors",[89],"2001-01",[4570,4571,34],"Brain and Central Nervous System Tumors","Metastatic Cancer",[4558],{"trials":4574,"activeCount":101},[],{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":101},[],{"intervention":2746,"totalTrials":134,"cells":4582},{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4584,"activeCount":101},[],{"trials":4586,"activeCount":101},[4587],{"nctId":2738,"briefTitle":2739,"status":541,"phases":4588,"primaryCompletion":2741,"completion":2741,"start":2741,"enrollment":101,"conditions":4589,"interventions":4590},[89],[2743,2744],[2746,2731,2747],{"trials":4592,"activeCount":101},[],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"intervention":2747,"totalTrials":134,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4609,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4602,"activeCount":101},[],{"trials":4604,"activeCount":101},[4605],{"nctId":2738,"briefTitle":2739,"status":541,"phases":4606,"primaryCompletion":2741,"completion":2741,"start":2741,"enrollment":101,"conditions":4607,"interventions":4608},[89],[2743,2744],[2746,2731,2747],{"trials":4610,"activeCount":101},[],{"trials":4612,"activeCount":101},[],{"trials":4614,"activeCount":101},[],{"trials":4616,"activeCount":101},[],{"intervention":4618,"totalTrials":134,"cells":4619},"Raltegravir and rifapentine",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4632,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4621,"activeCount":101},[],{"trials":4623,"activeCount":101},[4624],{"nctId":4625,"briefTitle":4626,"status":111,"phases":4627,"primaryCompletion":4628,"completion":2353,"start":1937,"enrollment":4629,"conditions":4630,"interventions":4631},"NCT00809718","The Effect of Rifapentine on Raltegravir",[89],"2011-05",27,[156],[4618],{"trials":4633,"activeCount":101},[],{"trials":4635,"activeCount":101},[],{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"intervention":2794,"totalTrials":134,"cells":4641},{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4650,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4643,"activeCount":101},[],{"trials":4645,"activeCount":101},[4646],{"nctId":2787,"briefTitle":2788,"status":111,"phases":4647,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":892,"conditions":4648,"interventions":4649},[89],[34],[2794,2780],{"trials":4651,"activeCount":101},[],{"trials":4653,"activeCount":101},[],{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"intervention":4659,"totalTrials":134,"cells":4660},"pemetrexed disodium",{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4672,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4662,"activeCount":101},[],{"trials":4664,"activeCount":101},[4665],{"nctId":4666,"briefTitle":4667,"status":111,"phases":4668,"primaryCompletion":4087,"completion":4087,"start":4669,"enrollment":3375,"conditions":4670,"interventions":4671},"NCT00003706","LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function",[89],"1998-04",[34],[4659],{"trials":4673,"activeCount":101},[],{"trials":4675,"activeCount":101},[],{"trials":4677,"activeCount":101},[],{"trials":4679,"activeCount":101},[],{"intervention":4681,"totalTrials":212,"cells":4682},"Triple Antibiotic Paste",{"EARLY_PHASE1":4683,"PHASE1":4700,"PHASE2":4702,"PHASE3":4704,"PHASE4":4706,"NA":4708},{"trials":4684,"activeCount":101},[4685,4694],{"nctId":4686,"briefTitle":4687,"status":111,"phases":4688,"primaryCompletion":2741,"completion":2741,"start":1938,"enrollment":97,"conditions":4689,"interventions":4691},"NCT00881491","Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste",[88],[4690],"Pulp Necrosis",[4692,4681,4693],"Double Antibiotic Paste","Mineral Trioxide Aggregate",{"nctId":4695,"briefTitle":4696,"status":111,"phases":4697,"primaryCompletion":3562,"completion":3562,"start":2378,"enrollment":134,"conditions":4698,"interventions":4699},"NCT00881907","Tissue Characterization in Teeth Treated With a Regeneration Protocol",[88],[4690],[4681,4681,4681],{"trials":4701,"activeCount":101},[],{"trials":4703,"activeCount":101},[],{"trials":4705,"activeCount":101},[],{"trials":4707,"activeCount":101},[],{"trials":4709,"activeCount":101},[],{"intervention":4711,"totalTrials":212,"cells":4712},"Ursolic Acid",{"EARLY_PHASE1":4713,"PHASE1":4735,"PHASE2":4737,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4714,"activeCount":101},[4715,4726],{"nctId":4716,"briefTitle":4717,"status":111,"phases":4718,"primaryCompletion":4719,"completion":4720,"start":4721,"enrollment":16,"conditions":4722,"interventions":4724},"NCT04421716","Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic Acid",[88],"2020-11-30","2021-04-16","2020-10-20",[4723],"Bioavailability of Phytonutrients",[4711,4725],"Curcumin",{"nctId":4727,"briefTitle":4728,"status":541,"phases":4729,"primaryCompletion":4730,"completion":4731,"start":4732,"enrollment":101,"conditions":4733,"interventions":4734},"NCT04403568","Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate",[88],"2022-12","2023-12","2021-10",[26],[4711,4725],{"trials":4736,"activeCount":101},[],{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":101},[],{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"intervention":4725,"totalTrials":212,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4757,"PHASE2":4759,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4748,"activeCount":101},[4749,4753],{"nctId":4716,"briefTitle":4717,"status":111,"phases":4750,"primaryCompletion":4719,"completion":4720,"start":4721,"enrollment":16,"conditions":4751,"interventions":4752},[88],[4723],[4711,4725],{"nctId":4727,"briefTitle":4728,"status":541,"phases":4754,"primaryCompletion":4730,"completion":4731,"start":4732,"enrollment":101,"conditions":4755,"interventions":4756},[88],[26],[4711,4725],{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[],{"trials":4762,"activeCount":101},[],{"trials":4764,"activeCount":101},[],{"trials":4766,"activeCount":101},[],{"intervention":4768,"totalTrials":134,"cells":4769},"Sirolimus",{"EARLY_PHASE1":4770,"PHASE1":4780,"PHASE2":4782,"PHASE3":4784,"PHASE4":4786,"NA":4788},{"trials":4771,"activeCount":101},[4772],{"nctId":4773,"briefTitle":4774,"status":111,"phases":4775,"primaryCompletion":4776,"completion":4777,"start":517,"enrollment":4503,"conditions":4778,"interventions":4779},"NCT02753309","A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer",[88],"2019-12-01","2021-03-02",[560],[4768],{"trials":4781,"activeCount":101},[],{"trials":4783,"activeCount":101},[],{"trials":4785,"activeCount":101},[],{"trials":4787,"activeCount":101},[],{"trials":4789,"activeCount":101},[],{"intervention":4791,"totalTrials":134,"cells":4792},"Xylocaine 2 % with 1:100,000 epinephrine",{"EARLY_PHASE1":4793,"PHASE1":4805,"PHASE2":4807,"PHASE3":4809,"PHASE4":4811,"NA":4813},{"trials":4794,"activeCount":101},[4795],{"nctId":4796,"briefTitle":4797,"status":111,"phases":4798,"primaryCompletion":4799,"completion":4799,"start":4800,"enrollment":925,"conditions":4801,"interventions":4803},"NCT06293807","Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine",[88],"2023-04-16","2022-06-06",[4802],"Periodontal Diseases",[4791,4804],"Bupivicaine 0.5% with 1:200,000 epinephrine",{"trials":4806,"activeCount":101},[],{"trials":4808,"activeCount":101},[],{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[],{"trials":4814,"activeCount":101},[],{"intervention":4804,"totalTrials":134,"cells":4816},{"EARLY_PHASE1":4817,"PHASE1":4823,"PHASE2":4825,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4818,"activeCount":101},[4819],{"nctId":4796,"briefTitle":4797,"status":111,"phases":4820,"primaryCompletion":4799,"completion":4799,"start":4800,"enrollment":925,"conditions":4821,"interventions":4822},[88],[4802],[4791,4804],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"trials":4828,"activeCount":101},[],{"trials":4830,"activeCount":101},[],{"trials":4832,"activeCount":101},[],{"intervention":4834,"totalTrials":134,"cells":4835},"Bupivacaine",{"EARLY_PHASE1":4836,"PHASE1":4847,"PHASE2":4849,"PHASE3":4851,"PHASE4":4853,"NA":4855},{"trials":4837,"activeCount":101},[4838],{"nctId":4839,"briefTitle":4840,"status":111,"phases":4841,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":19,"conditions":4844,"interventions":4846},"NCT05794828","Erector Spinae Regional Anesthesia for Pain Control",[88],"2025-02-18","2023-09-15",[4845],"Pain Management",[4834],{"trials":4848,"activeCount":101},[],{"trials":4850,"activeCount":101},[],{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":101},[],{"trials":4856,"activeCount":101},[],{"intervention":4858,"totalTrials":134,"cells":4859},"Glucagon",{"EARLY_PHASE1":4860,"PHASE1":4870,"PHASE2":4872,"PHASE3":4874,"PHASE4":4876,"NA":4878},{"trials":4861,"activeCount":101},[4862],{"nctId":4863,"briefTitle":4864,"status":111,"phases":4865,"primaryCompletion":4866,"completion":4866,"start":4867,"enrollment":97,"conditions":4868,"interventions":4869},"NCT04300049","Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism",[88],"2023-11-15","2018-02-05",[1800],[4858],{"trials":4871,"activeCount":101},[],{"trials":4873,"activeCount":101},[],{"trials":4875,"activeCount":101},[],{"trials":4877,"activeCount":101},[],{"trials":4879,"activeCount":101},[],{"intervention":1971,"totalTrials":134,"cells":4881},{"EARLY_PHASE1":4882,"PHASE1":4888,"PHASE2":4890,"PHASE3":4892,"PHASE4":4894,"NA":4896},{"trials":4883,"activeCount":101},[4884],{"nctId":1961,"briefTitle":1962,"status":111,"phases":4885,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":19,"conditions":4886,"interventions":4887},[88],[1968],[1956,1970,1971],{"trials":4889,"activeCount":101},[],{"trials":4891,"activeCount":101},[],{"trials":4893,"activeCount":101},[],{"trials":4895,"activeCount":101},[],{"trials":4897,"activeCount":101},[],{"intervention":4692,"totalTrials":134,"cells":4899},{"EARLY_PHASE1":4900,"PHASE1":4906,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4914},{"trials":4901,"activeCount":101},[4902],{"nctId":4686,"briefTitle":4687,"status":111,"phases":4903,"primaryCompletion":2741,"completion":2741,"start":1938,"enrollment":97,"conditions":4904,"interventions":4905},[88],[4690],[4692,4681,4693],{"trials":4907,"activeCount":101},[],{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[],{"trials":4915,"activeCount":101},[],{"intervention":4693,"totalTrials":134,"cells":4917},{"EARLY_PHASE1":4918,"PHASE1":4924,"PHASE2":4926,"PHASE3":4928,"PHASE4":4930,"NA":4932},{"trials":4919,"activeCount":101},[4920],{"nctId":4686,"briefTitle":4687,"status":111,"phases":4921,"primaryCompletion":2741,"completion":2741,"start":1938,"enrollment":97,"conditions":4922,"interventions":4923},[88],[4690],[4692,4681,4693],{"trials":4925,"activeCount":101},[],{"trials":4927,"activeCount":101},[],{"trials":4929,"activeCount":101},[],{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":101},[],{"intervention":4935,"totalTrials":134,"cells":4936},"Imipramine",{"EARLY_PHASE1":4937,"PHASE1":4948,"PHASE2":4950,"PHASE3":4952,"PHASE4":4954,"NA":4956},{"trials":4938,"activeCount":101},[4939],{"nctId":4940,"briefTitle":4941,"status":111,"phases":4942,"primaryCompletion":4943,"completion":557,"start":4944,"enrollment":4945,"conditions":4946,"interventions":4947},"NCT03122444","Imipramine on ER+ve and Triple Negative Breast Cancer",[88],"2022-03-01","2019-07-05",17,[18],[4935],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[],{"trials":4953,"activeCount":101},[],{"trials":4955,"activeCount":101},[],{"trials":4957,"activeCount":101},[],{"intervention":4959,"totalTrials":134,"cells":4960},"REMD-477",{"EARLY_PHASE1":4961,"PHASE1":4972,"PHASE2":4974,"PHASE3":4976,"PHASE4":4978,"NA":4980},{"trials":4962,"activeCount":101},[4963],{"nctId":4964,"briefTitle":4965,"status":111,"phases":4966,"primaryCompletion":4967,"completion":4967,"start":4968,"enrollment":1885,"conditions":4969,"interventions":4971},"NCT05093517","Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM",[88],"2022-03-16","2021-11-10",[15,4970,1800],"Glucose Tolerance Impaired",[4959],{"trials":4973,"activeCount":101},[],{"trials":4975,"activeCount":101},[],{"trials":4977,"activeCount":101},[],{"trials":4979,"activeCount":101},[],{"trials":4981,"activeCount":101},[],{"intervention":4983,"totalTrials":134,"cells":4984},"Letrozole",{"EARLY_PHASE1":4985,"PHASE1":4995,"PHASE2":4997,"PHASE3":4999,"PHASE4":5001,"NA":5003},{"trials":4986,"activeCount":101},[4987],{"nctId":4988,"briefTitle":4989,"status":111,"phases":4990,"primaryCompletion":4991,"completion":4992,"start":968,"enrollment":413,"conditions":4993,"interventions":4994},"NCT02538484","Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects",[88],"2020-03-11","2020-03-26",[18],[4983],{"trials":4996,"activeCount":101},[],{"trials":4998,"activeCount":101},[],{"trials":5000,"activeCount":101},[],{"trials":5002,"activeCount":101},[],{"trials":5004,"activeCount":101},[],{"intervention":5006,"totalTrials":134,"cells":5007},"Alpha Lipoic Acid 300mg",{"EARLY_PHASE1":5008,"PHASE1":5020,"PHASE2":5022,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5009,"activeCount":101},[5010],{"nctId":5011,"briefTitle":5012,"status":541,"phases":5013,"primaryCompletion":5014,"completion":5015,"start":4300,"enrollment":101,"conditions":5016,"interventions":5018},"NCT05945160","Vestibular Function Using Mitochondrial Antioxidant Therapy",[88],"2024-08","2024-12",[5017],"Vestibular Function Disorder",[5006,5019],"Coenzyme Q10 200mg",{"trials":5021,"activeCount":101},[],{"trials":5023,"activeCount":101},[],{"trials":5025,"activeCount":101},[],{"trials":5027,"activeCount":101},[],{"trials":5029,"activeCount":101},[],{"intervention":5019,"totalTrials":134,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5038,"PHASE2":5040,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5033,"activeCount":101},[5034],{"nctId":5011,"briefTitle":5012,"status":541,"phases":5035,"primaryCompletion":5014,"completion":5015,"start":4300,"enrollment":101,"conditions":5036,"interventions":5037},[88],[5017],[5006,5019],{"trials":5039,"activeCount":101},[],{"trials":5041,"activeCount":101},[],{"trials":5043,"activeCount":101},[],{"trials":5045,"activeCount":101},[],{"trials":5047,"activeCount":101},[],{"intervention":5049,"totalTrials":134,"cells":5050},"Botnia Clamp",{"EARLY_PHASE1":5051,"PHASE1":5062,"PHASE2":5064,"PHASE3":5066,"PHASE4":5068,"NA":5070},{"trials":5052,"activeCount":101},[5053],{"nctId":5054,"briefTitle":5055,"status":1030,"phases":5056,"primaryCompletion":5057,"completion":5057,"start":5058,"enrollment":413,"conditions":5059,"interventions":5061},"NCT04515472","Effect of Gender Affirming Hormone Therapy on Glucose Metabolism",[88],"2025-03-17","2020-06-17",[5060],"Transgender Persons",[5049],{"trials":5063,"activeCount":101},[],{"trials":5065,"activeCount":101},[],{"trials":5067,"activeCount":101},[],{"trials":5069,"activeCount":101},[],{"trials":5071,"activeCount":101},[],{"intervention":5073,"totalTrials":134,"cells":5074},"Omeprazole",{"EARLY_PHASE1":5075,"PHASE1":5084,"PHASE2":5086,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5076,"activeCount":101},[5077],{"nctId":5078,"briefTitle":5079,"status":111,"phases":5080,"primaryCompletion":247,"completion":247,"start":2577,"enrollment":830,"conditions":5081,"interventions":5083},"NCT02844621","Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older Adults",[88],[5082],"Healthy Volunteers",[5073],{"trials":5085,"activeCount":101},[],{"trials":5087,"activeCount":101},[],{"trials":5089,"activeCount":101},[],{"trials":5091,"activeCount":101},[],{"trials":5093,"activeCount":101},[],{"intervention":5095,"totalTrials":134,"cells":5096},"Mirabegron",{"EARLY_PHASE1":5097,"PHASE1":5111,"PHASE2":5113,"PHASE3":5115,"PHASE4":5117,"NA":5119},{"trials":5098,"activeCount":101},[5099],{"nctId":5100,"briefTitle":5101,"status":111,"phases":5102,"primaryCompletion":5103,"completion":5104,"start":5105,"enrollment":351,"conditions":5106,"interventions":5110},"NCT03612401","Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron",[88],"2020-03-23","2021-03-31","2018-12-05",[5107,5108,5109],"Spinal Cord Injuries","Neurogenic Bladder","Cognitive Change",[5095],{"trials":5112,"activeCount":101},[],{"trials":5114,"activeCount":101},[],{"trials":5116,"activeCount":101},[],{"trials":5118,"activeCount":101},[],{"trials":5120,"activeCount":101},[],{"intervention":5122,"totalTrials":134,"cells":5123},"S-equol",{"EARLY_PHASE1":5124,"PHASE1":5135,"PHASE2":5137,"PHASE3":5139,"PHASE4":5141,"NA":5143},{"trials":5125,"activeCount":101},[5126],{"nctId":5127,"briefTitle":5128,"status":111,"phases":5129,"primaryCompletion":5130,"completion":5131,"start":5132,"enrollment":186,"conditions":5133,"interventions":5134},"NCT02352025","S-equol in Women With Triple Negative Breast Cancer",[88],"2019-04-10","2020-06-30","2015-04-15",[18],[5122],{"trials":5136,"activeCount":101},[],{"trials":5138,"activeCount":101},[],{"trials":5140,"activeCount":101},[],{"trials":5142,"activeCount":101},[],{"trials":5144,"activeCount":101},[],{"intervention":5146,"totalTrials":134,"cells":5147},"Rapamycin 8% Ointment",{"EARLY_PHASE1":5148,"PHASE1":5160,"PHASE2":5162,"PHASE3":5164,"PHASE4":5166,"NA":5168},{"trials":5149,"activeCount":101},[5150],{"nctId":5151,"briefTitle":5152,"status":111,"phases":5153,"primaryCompletion":5154,"completion":5155,"start":5156,"enrollment":1885,"conditions":5157,"interventions":5159},"NCT04049552","RAPA-Keloid Study of Keloid Regression",[88],"2020-08-24","2021-05-02","2020-01-24",[5158],"Keloid",[5146],{"trials":5161,"activeCount":101},[],{"trials":5163,"activeCount":101},[],{"trials":5165,"activeCount":101},[],{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[],{"intervention":5171,"totalTrials":134,"cells":5172},"Deferiprone",{"EARLY_PHASE1":5173,"PHASE1":5184,"PHASE2":5186,"PHASE3":5188,"PHASE4":5190,"NA":5192},{"trials":5174,"activeCount":101},[5175],{"nctId":5176,"briefTitle":5177,"status":541,"phases":5178,"primaryCompletion":5179,"completion":5180,"start":5181,"enrollment":101,"conditions":5182,"interventions":5183},"NCT02878538","A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment",[88],"2022-04","2023-04","2018-01",[535],[5171],{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":101},[],{"trials":5189,"activeCount":101},[],{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[],{"intervention":5195,"totalTrials":134,"cells":5196},"Rapamune",{"EARLY_PHASE1":5197,"PHASE1":5208,"PHASE2":5210,"PHASE3":5212,"PHASE4":5214,"NA":5216},{"trials":5198,"activeCount":101},[5199],{"nctId":5200,"briefTitle":5201,"status":111,"phases":5202,"primaryCompletion":5203,"completion":5203,"start":5204,"enrollment":97,"conditions":5205,"interventions":5207},"NCT04200911","Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway",[88],"2022-01-13","2020-06-01",[5206,536],"Cognitive Impairment, Mild",[5195],{"trials":5209,"activeCount":101},[],{"trials":5211,"activeCount":101},[],{"trials":5213,"activeCount":101},[],{"trials":5215,"activeCount":101},[],{"trials":5217,"activeCount":101},[],{"intervention":5219,"totalTrials":134,"cells":5220},"Oxycodone\u002FPlacebo",{"EARLY_PHASE1":5221,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5242,"NA":5244},{"trials":5222,"activeCount":101},[5223],{"nctId":5224,"briefTitle":5225,"status":1030,"phases":5226,"primaryCompletion":5227,"completion":5228,"start":5229,"enrollment":895,"conditions":5230,"interventions":5233},"NCT03837860","Reducing the Abuse of Opioids in Drug Users",[88],"2021-03-23","2022-01-21","2019-04-01",[5231,5232],"Opioid Abuse, Unspecified","Opioid Dependence",[5219,5234,5235],"Oxycodone\u002FRisperidone","Oxycodone\u002FZiprasidone",{"trials":5237,"activeCount":101},[],{"trials":5239,"activeCount":101},[],{"trials":5241,"activeCount":101},[],{"trials":5243,"activeCount":101},[],{"trials":5245,"activeCount":101},[],{"intervention":5234,"totalTrials":134,"cells":5247},{"EARLY_PHASE1":5248,"PHASE1":5254,"PHASE2":5256,"PHASE3":5258,"PHASE4":5260,"NA":5262},{"trials":5249,"activeCount":101},[5250],{"nctId":5224,"briefTitle":5225,"status":1030,"phases":5251,"primaryCompletion":5227,"completion":5228,"start":5229,"enrollment":895,"conditions":5252,"interventions":5253},[88],[5231,5232],[5219,5234,5235],{"trials":5255,"activeCount":101},[],{"trials":5257,"activeCount":101},[],{"trials":5259,"activeCount":101},[],{"trials":5261,"activeCount":101},[],{"trials":5263,"activeCount":101},[],{"intervention":5235,"totalTrials":134,"cells":5265},{"EARLY_PHASE1":5266,"PHASE1":5272,"PHASE2":5274,"PHASE3":5276,"PHASE4":5278,"NA":5280},{"trials":5267,"activeCount":101},[5268],{"nctId":5224,"briefTitle":5225,"status":1030,"phases":5269,"primaryCompletion":5227,"completion":5228,"start":5229,"enrollment":895,"conditions":5270,"interventions":5271},[88],[5231,5232],[5219,5234,5235],{"trials":5273,"activeCount":101},[],{"trials":5275,"activeCount":101},[],{"trials":5277,"activeCount":101},[],{"trials":5279,"activeCount":101},[],{"trials":5281,"activeCount":101},[],{"intervention":5283,"totalTrials":134,"cells":5284},"Juven",{"EARLY_PHASE1":5285,"PHASE1":5298,"PHASE2":5300,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5286,"activeCount":101},[5287],{"nctId":5288,"briefTitle":5289,"status":111,"phases":5290,"primaryCompletion":5291,"completion":5292,"start":5293,"enrollment":533,"conditions":5294,"interventions":5296},"NCT05971173","Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery",[88],"2024-12-10","2025-06-04","2023-09-28",[5295],"Hip Fractures",[5283,5297],"Centrum Silver 50+",{"trials":5299,"activeCount":101},[],{"trials":5301,"activeCount":101},[],{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[],{"trials":5307,"activeCount":101},[],{"intervention":5297,"totalTrials":134,"cells":5309},{"EARLY_PHASE1":5310,"PHASE1":5316,"PHASE2":5318,"PHASE3":5320,"PHASE4":5322,"NA":5324},{"trials":5311,"activeCount":101},[5312],{"nctId":5288,"briefTitle":5289,"status":111,"phases":5313,"primaryCompletion":5291,"completion":5292,"start":5293,"enrollment":533,"conditions":5314,"interventions":5315},[88],[5295],[5283,5297],{"trials":5317,"activeCount":101},[],{"trials":5319,"activeCount":101},[],{"trials":5321,"activeCount":101},[],{"trials":5323,"activeCount":101},[],{"trials":5325,"activeCount":101},[],{"intervention":5327,"totalTrials":134,"cells":5328},"Dexamethasone 4mg\u002Fml solution",{"EARLY_PHASE1":5329,"PHASE1":5342,"PHASE2":5344,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5330,"activeCount":101},[5331],{"nctId":5332,"briefTitle":5333,"status":111,"phases":5334,"primaryCompletion":5335,"completion":5335,"start":5336,"enrollment":5337,"conditions":5338,"interventions":5341},"NCT06556095","Ridge Preservation With FDBA (Freeze Dried Bone Allograft) Using Dexamethasone vs. Saline",[88],"2026-01-08","2024-09-16",44,[5339,5340],"Bone Graft","Tooth Extraction",[5327],{"trials":5343,"activeCount":101},[],{"trials":5345,"activeCount":101},[],{"trials":5347,"activeCount":101},[],{"trials":5349,"activeCount":101},[],{"trials":5351,"activeCount":101},[],{"intervention":5353,"totalTrials":134,"cells":5354},"Quetiapine Fumarate",{"EARLY_PHASE1":5355,"PHASE1":5367,"PHASE2":5369,"PHASE3":5371,"PHASE4":5373,"NA":5375},{"trials":5356,"activeCount":101},[5357],{"nctId":5358,"briefTitle":5359,"status":111,"phases":5360,"primaryCompletion":5361,"completion":5362,"start":5363,"enrollment":1493,"conditions":5364,"interventions":5366},"NCT04280965","Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury",[88],"2022-04-29","2022-10-17","2019-02-01",[5365],"Post Traumatic Stress Disorder",[5353],{"trials":5368,"activeCount":101},[],{"trials":5370,"activeCount":101},[],{"trials":5372,"activeCount":101},[],{"trials":5374,"activeCount":101},[],{"trials":5376,"activeCount":101},[],{"intervention":5378,"totalTrials":134,"cells":5379},"Aspirin",{"EARLY_PHASE1":5380,"PHASE1":5391,"PHASE2":5393,"PHASE3":5395,"PHASE4":5397,"NA":5399},{"trials":5381,"activeCount":101},[5382],{"nctId":5383,"briefTitle":5384,"status":111,"phases":5385,"primaryCompletion":968,"completion":968,"start":5386,"enrollment":5387,"conditions":5388,"interventions":5390},"NCT02062255","Impact of COX2 on Sera Biomarkers From Obese Subjects",[88],"2013-10",126,[5389],"Breast Cancer Survivors",[5378],{"trials":5392,"activeCount":101},[],{"trials":5394,"activeCount":101},[],{"trials":5396,"activeCount":101},[],{"trials":5398,"activeCount":101},[],{"trials":5400,"activeCount":101},[],{"intervention":5402,"totalTrials":134,"cells":5403},"Rapamycin Topical Ointment",{"EARLY_PHASE1":5404,"PHASE1":5416,"PHASE2":5418,"PHASE3":5420,"PHASE4":5422,"NA":5424},{"trials":5405,"activeCount":101},[5406],{"nctId":5407,"briefTitle":5408,"status":111,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":5411,"enrollment":892,"conditions":5412,"interventions":5415},"NCT04608448","Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock",[88],"2022-04-15","2021-04-28",[24,5413,5414],"Epigenetics","Inflammatory Mediators",[5402],{"trials":5417,"activeCount":101},[],{"trials":5419,"activeCount":101},[],{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[],{"trials":5425,"activeCount":101},[],{"intervention":5427,"totalTrials":134,"cells":5428},"Bacillus Calmette-Guerin",{"EARLY_PHASE1":5429,"PHASE1":5437,"PHASE2":5439,"PHASE3":5441,"PHASE4":5443,"NA":5445},{"trials":5430,"activeCount":101},[5431],{"nctId":5432,"briefTitle":5433,"status":111,"phases":5434,"primaryCompletion":2159,"completion":2159,"start":5386,"enrollment":830,"conditions":5435,"interventions":5436},"NCT02326168","PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer",[88],[560],[5427],{"trials":5438,"activeCount":101},[],{"trials":5440,"activeCount":101},[],{"trials":5442,"activeCount":101},[],{"trials":5444,"activeCount":101},[],{"trials":5446,"activeCount":101},[],{"intervention":5448,"totalTrials":134,"cells":5449},"normal saline control",{"EARLY_PHASE1":5450,"PHASE1":5462,"PHASE2":5464,"PHASE3":5466,"PHASE4":5468,"NA":5470},{"trials":5451,"activeCount":101},[5452],{"nctId":5453,"briefTitle":5454,"status":1030,"phases":5455,"primaryCompletion":1938,"completion":2033,"start":3662,"enrollment":5456,"conditions":5457,"interventions":5460},"NCT00420407","Low Dose Vasopressin in Traumatic Shock",[88],81,[5458,5459],"Injuries","Shock, Traumatic",[5448,5461],"vasopressin",{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[],{"trials":5469,"activeCount":101},[],{"trials":5471,"activeCount":101},[],{"intervention":5461,"totalTrials":134,"cells":5473},{"EARLY_PHASE1":5474,"PHASE1":5480,"PHASE2":5482,"PHASE3":5484,"PHASE4":5486,"NA":5488},{"trials":5475,"activeCount":101},[5476],{"nctId":5453,"briefTitle":5454,"status":1030,"phases":5477,"primaryCompletion":1938,"completion":2033,"start":3662,"enrollment":5456,"conditions":5478,"interventions":5479},[88],[5458,5459],[5448,5461],{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[],{"trials":5489,"activeCount":101},[],{"intervention":1970,"totalTrials":212,"cells":5491},{"EARLY_PHASE1":5492,"PHASE1":5498,"PHASE2":5500,"PHASE3":5502,"PHASE4":5504,"NA":5506},{"trials":5493,"activeCount":101},[5494],{"nctId":1961,"briefTitle":1962,"status":111,"phases":5495,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":19,"conditions":5496,"interventions":5497},[88],[1968],[1956,1970,1971],{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":101},[],{"trials":5503,"activeCount":101},[],{"trials":5505,"activeCount":101},[],{"trials":5507,"activeCount":101},[5508],{"nctId":5509,"briefTitle":5510,"status":111,"phases":5511,"primaryCompletion":979,"completion":5512,"start":2600,"enrollment":413,"conditions":5513,"interventions":5515},"NCT00538642","Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone",[93],"2011-11",[21,5514,29],"Schizoaffective Disorder",[5516],"ziprasidone",{"intervention":5518,"totalTrials":212,"cells":5519},"aripiprazole",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5539},{"trials":5521,"activeCount":101},[],{"trials":5523,"activeCount":101},[],{"trials":5525,"activeCount":101},[],{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":101},[5530],{"nctId":5531,"briefTitle":5532,"status":111,"phases":5533,"primaryCompletion":5534,"completion":5534,"start":5535,"enrollment":592,"conditions":5536,"interventions":5537},"NCT00223496","12- Week Open Label Treatment of Refractory Bipolar Depression",[92],"2009-09","2004-09",[29],[5538],"Aripiprazole",{"trials":5540,"activeCount":101},[5541],{"nctId":5542,"briefTitle":5543,"status":111,"phases":5544,"primaryCompletion":153,"completion":153,"start":114,"enrollment":154,"conditions":5545,"interventions":5547},"NCT00223418","Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills",[93],[5546,5514],"Schizophenia Disorder",[5518],{"intervention":5549,"totalTrials":134,"cells":5550},"mucomyst",{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5557,"PHASE4":5559,"NA":5561},{"trials":5552,"activeCount":101},[],{"trials":5554,"activeCount":101},[],{"trials":5556,"activeCount":101},[],{"trials":5558,"activeCount":101},[],{"trials":5560,"activeCount":101},[],{"trials":5562,"activeCount":101},[5563],{"nctId":5564,"briefTitle":5565,"status":111,"phases":5566,"completion":5567,"start":5568,"enrollment":5569,"conditions":5570,"interventions":5573},"NCT00131521","Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit",[93],"2007-12","2005-01",260,[5571,5572],"Mucus Obstruction","Intubation",[5549,5574],"sodium chloride",{"intervention":5574,"totalTrials":134,"cells":5576},{"EARLY_PHASE1":5577,"PHASE1":5579,"PHASE2":5581,"PHASE3":5583,"PHASE4":5585,"NA":5587},{"trials":5578,"activeCount":101},[],{"trials":5580,"activeCount":101},[],{"trials":5582,"activeCount":101},[],{"trials":5584,"activeCount":101},[],{"trials":5586,"activeCount":101},[],{"trials":5588,"activeCount":101},[5589],{"nctId":5564,"briefTitle":5565,"status":111,"phases":5590,"completion":5567,"start":5568,"enrollment":5569,"conditions":5591,"interventions":5592},[93],[5571,5572],[5549,5574],{"intervention":5594,"totalTrials":134,"cells":5595},"Intralipid 20%",{"EARLY_PHASE1":5596,"PHASE1":5598,"PHASE2":5600,"PHASE3":5602,"PHASE4":5604,"NA":5606},{"trials":5597,"activeCount":101},[],{"trials":5599,"activeCount":101},[],{"trials":5601,"activeCount":101},[],{"trials":5603,"activeCount":101},[],{"trials":5605,"activeCount":101},[],{"trials":5607,"activeCount":101},[5608],{"nctId":5609,"briefTitle":5610,"status":111,"phases":5611,"primaryCompletion":5612,"completion":5613,"start":5614,"enrollment":22,"conditions":5615,"interventions":5617},"NCT01740817","A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling",[93],"2013-12","2015-09","2008-01",[394,5616],"Obesity",[5594,5618],"Saline",{"intervention":5618,"totalTrials":134,"cells":5620},{"EARLY_PHASE1":5621,"PHASE1":5623,"PHASE2":5625,"PHASE3":5627,"PHASE4":5629,"NA":5631},{"trials":5622,"activeCount":101},[],{"trials":5624,"activeCount":101},[],{"trials":5626,"activeCount":101},[],{"trials":5628,"activeCount":101},[],{"trials":5630,"activeCount":101},[],{"trials":5632,"activeCount":101},[5633],{"nctId":5609,"briefTitle":5610,"status":111,"phases":5634,"primaryCompletion":5612,"completion":5613,"start":5614,"enrollment":22,"conditions":5635,"interventions":5636},[93],[394,5616],[5594,5618],{"intervention":5638,"totalTrials":134,"cells":5639},"ketamine",{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5644,"PHASE3":5646,"PHASE4":5648,"NA":5650},{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":101},[],{"trials":5645,"activeCount":101},[],{"trials":5647,"activeCount":101},[],{"trials":5649,"activeCount":101},[],{"trials":5651,"activeCount":101},[5652],{"nctId":5653,"briefTitle":5654,"status":1030,"phases":5655,"primaryCompletion":978,"completion":978,"start":2440,"enrollment":22,"conditions":5656,"interventions":5658},"NCT02422303","Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms",[93],[1942,5657],"Major Depressive Disorder",[5638],{"intervention":5660,"totalTrials":134,"cells":5661},"0.9% Sodium Chloride irrigation solution",{"EARLY_PHASE1":5662,"PHASE1":5664,"PHASE2":5666,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5663,"activeCount":101},[],{"trials":5665,"activeCount":101},[],{"trials":5667,"activeCount":101},[],{"trials":5669,"activeCount":101},[],{"trials":5671,"activeCount":101},[],{"trials":5673,"activeCount":101},[5674],{"nctId":5675,"briefTitle":5676,"status":111,"phases":5677,"primaryCompletion":5678,"completion":5678,"start":164,"enrollment":3058,"conditions":5679,"interventions":5682},"NCT01066624","Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation",[93],"2014-01",[5680,5681],"Mucositis","Multiple Myeloma",[5660],{"intervention":5684,"totalTrials":134,"cells":5685},"Canagliflozin",{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5692,"PHASE4":5694,"NA":5696},{"trials":5687,"activeCount":101},[],{"trials":5689,"activeCount":101},[],{"trials":5691,"activeCount":101},[],{"trials":5693,"activeCount":101},[],{"trials":5695,"activeCount":101},[],{"trials":5697,"activeCount":101},[5698],{"nctId":5699,"briefTitle":5700,"status":111,"phases":5701,"primaryCompletion":5702,"completion":2754,"start":5703,"enrollment":1985,"conditions":5704,"interventions":5705},"NCT02324842","Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients",[93],"2018-03-28","2014-11",[188],[5684,5706],"Liraglutide",{"intervention":5706,"totalTrials":134,"cells":5708},{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5710,"activeCount":101},[],{"trials":5712,"activeCount":101},[],{"trials":5714,"activeCount":101},[],{"trials":5716,"activeCount":101},[],{"trials":5718,"activeCount":101},[],{"trials":5720,"activeCount":101},[5721],{"nctId":5699,"briefTitle":5700,"status":111,"phases":5722,"primaryCompletion":5702,"completion":2754,"start":5703,"enrollment":1985,"conditions":5723,"interventions":5724},[93],[188],[5684,5706],{"intervention":5726,"totalTrials":134,"cells":5727},"Mannitol",{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5729,"activeCount":101},[],{"trials":5731,"activeCount":101},[],{"trials":5733,"activeCount":101},[],{"trials":5735,"activeCount":101},[],{"trials":5737,"activeCount":101},[],{"trials":5739,"activeCount":101},[5740],{"nctId":5741,"briefTitle":5742,"status":1030,"phases":5743,"primaryCompletion":142,"completion":142,"start":1950,"enrollment":97,"conditions":5744,"interventions":5747},"NCT00125229","Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients",[],[5745,5746],"Traumatic Brain Injury","Intracranial Hypertension",[5726,5748],"Hypertonic Saline",{"intervention":5748,"totalTrials":134,"cells":5750},{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5755,"PHASE3":5757,"PHASE4":5759,"NA":5761},{"trials":5752,"activeCount":101},[],{"trials":5754,"activeCount":101},[],{"trials":5756,"activeCount":101},[],{"trials":5758,"activeCount":101},[],{"trials":5760,"activeCount":101},[],{"trials":5762,"activeCount":101},[5763],{"nctId":5741,"briefTitle":5742,"status":1030,"phases":5764,"primaryCompletion":142,"completion":142,"start":1950,"enrollment":97,"conditions":5765,"interventions":5766},[],[5745,5746],[5726,5748],{"intervention":5768,"totalTrials":134,"cells":5769},"BCG strain of Mycobacterium bovis",{"EARLY_PHASE1":5770,"PHASE1":5772,"PHASE2":5774,"PHASE3":5776,"PHASE4":5778,"NA":5780},{"trials":5771,"activeCount":101},[],{"trials":5773,"activeCount":101},[],{"trials":5775,"activeCount":101},[],{"trials":5777,"activeCount":101},[],{"trials":5779,"activeCount":101},[],{"trials":5781,"activeCount":101},[5782],{"nctId":5783,"briefTitle":5784,"status":1030,"phases":5785,"primaryCompletion":5786,"completion":5787,"start":3271,"enrollment":860,"conditions":5788,"interventions":5789},"NCT02365207","Intravesical BCG Administration to Patients With Invasive Bladder Cancer",[93],"2018-09-30","2019-04-25",[560],[5768],{"intervention":5791,"totalTrials":134,"cells":5792},"Isolation of genomic DNA",{"EARLY_PHASE1":5793,"PHASE1":5795,"PHASE2":5797,"PHASE3":5799,"PHASE4":5801,"NA":5803},{"trials":5794,"activeCount":101},[],{"trials":5796,"activeCount":101},[],{"trials":5798,"activeCount":101},[],{"trials":5800,"activeCount":101},[],{"trials":5802,"activeCount":101},[],{"trials":5804,"activeCount":101},[5805],{"nctId":5806,"briefTitle":5807,"status":111,"phases":5808,"primaryCompletion":5809,"completion":5810,"start":5811,"enrollment":5812,"conditions":5813,"interventions":5815},"NCT00223483","Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers",[],"2020-12-11","2021-07-14","2005-03",512,[5814,5082],"Hematologic Diseases",[5791],{"intervention":5817,"totalTrials":134,"cells":5818},"Capsaicin 8% Patch",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5820,"activeCount":101},[],{"trials":5822,"activeCount":101},[],{"trials":5824,"activeCount":101},[],{"trials":5826,"activeCount":101},[],{"trials":5828,"activeCount":101},[],{"trials":5830,"activeCount":101},[5831],{"nctId":5832,"briefTitle":5833,"status":111,"phases":5834,"primaryCompletion":5835,"completion":5836,"start":968,"enrollment":27,"conditions":5837,"interventions":5839},"NCT02441660","Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain",[93],"2021-07-31","2022-05-02",[5107,5838],"Neuropathic Pain",[5817,5840],"Low Dose Capsaicin 0.025% Well Patch",{"intervention":5840,"totalTrials":134,"cells":5842},{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5844,"activeCount":101},[],{"trials":5846,"activeCount":101},[],{"trials":5848,"activeCount":101},[],{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"trials":5854,"activeCount":101},[5855],{"nctId":5832,"briefTitle":5833,"status":111,"phases":5856,"primaryCompletion":5835,"completion":5836,"start":968,"enrollment":27,"conditions":5857,"interventions":5858},[93],[5107,5838],[5817,5840],{"intervention":5860,"totalTrials":134,"cells":5861},"Spironolactone and patiromer",{"EARLY_PHASE1":5862,"PHASE1":5864,"PHASE2":5866,"PHASE3":5868,"PHASE4":5870,"NA":5872},{"trials":5863,"activeCount":101},[],{"trials":5865,"activeCount":101},[],{"trials":5867,"activeCount":101},[],{"trials":5869,"activeCount":101},[],{"trials":5871,"activeCount":101},[],{"trials":5873,"activeCount":101},[5874],{"nctId":5875,"briefTitle":5876,"status":111,"phases":5877,"primaryCompletion":5878,"completion":5878,"start":978,"enrollment":5879,"conditions":5880,"interventions":5882},"NCT02823626","High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure",[],"2018-04",48,[5881],"Acute Decompensated Heart Failure",[5860],{"intervention":5884,"totalTrials":134,"cells":5885},"Intravenous Lipid Emulsion Comprised of Fish Oil",{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5890,"PHASE3":5892,"PHASE4":5894,"NA":5896},{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[],{"trials":5891,"activeCount":101},[],{"trials":5893,"activeCount":101},[],{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[5898],{"nctId":5899,"briefTitle":5900,"status":5901,"phases":5902,"conditions":5903,"interventions":5904},"NCT01425567","Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury","APPROVED_FOR_MARKETING",[],[3334],[5884],{"intervention":5906,"totalTrials":134,"cells":5907},"COVID-19 Vaccine",{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5912,"PHASE3":5914,"PHASE4":5916,"NA":5918},{"trials":5909,"activeCount":101},[],{"trials":5911,"activeCount":101},[],{"trials":5913,"activeCount":101},[],{"trials":5915,"activeCount":101},[],{"trials":5917,"activeCount":101},[],{"trials":5919,"activeCount":101},[5920],{"nctId":5921,"briefTitle":5922,"status":111,"phases":5923,"primaryCompletion":5924,"completion":5924,"start":5925,"enrollment":3375,"conditions":5926,"interventions":5927},"NCT04784689","Host Immune Response to Novel RNA COVID-19 Vaccination",[],"2022-05-18","2021-02-24",[5906,1882],[5906],{"intervention":5929,"totalTrials":134,"cells":5930},"heparin",{"EARLY_PHASE1":5931,"PHASE1":5933,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5932,"activeCount":101},[],{"trials":5934,"activeCount":101},[],{"trials":5936,"activeCount":101},[],{"trials":5938,"activeCount":101},[],{"trials":5940,"activeCount":101},[],{"trials":5942,"activeCount":101},[5943],{"nctId":5944,"briefTitle":5945,"status":541,"phases":5946,"primaryCompletion":1798,"completion":4628,"start":5947,"enrollment":101,"conditions":5948,"interventions":5952},"NCT00879957","Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates",[93],"2010-01",[5949,5950,5951],"Infant, Premature","Anticoagulants","Thrombosis",[5929,5953],"No heparin",{"intervention":5953,"totalTrials":134,"cells":5955},{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5966},{"trials":5957,"activeCount":101},[],{"trials":5959,"activeCount":101},[],{"trials":5961,"activeCount":101},[],{"trials":5963,"activeCount":101},[],{"trials":5965,"activeCount":101},[],{"trials":5967,"activeCount":101},[5968],{"nctId":5944,"briefTitle":5945,"status":541,"phases":5969,"primaryCompletion":1798,"completion":4628,"start":5947,"enrollment":101,"conditions":5970,"interventions":5971},[93],[5949,5950,5951],[5929,5953],{"intervention":5973,"totalTrials":134,"cells":5974},"MLN8237",{"EARLY_PHASE1":5975,"PHASE1":5977,"PHASE2":5979,"PHASE3":5981,"PHASE4":5983,"NA":5985},{"trials":5976,"activeCount":101},[],{"trials":5978,"activeCount":101},[],{"trials":5980,"activeCount":101},[],{"trials":5982,"activeCount":101},[],{"trials":5984,"activeCount":101},[],{"trials":5986,"activeCount":101},[5987],{"nctId":5988,"briefTitle":5989,"status":1701,"phases":5990,"conditions":5991,"interventions":5992},"NCT03005262","MLN8237 for a Subject With Adenocarcinoma of the Prostate",[],[26],[5973],{"intervention":5994,"totalTrials":134,"cells":5995},"IPA",{"EARLY_PHASE1":5996,"PHASE1":5998,"PHASE2":6000,"PHASE3":6002,"PHASE4":6004,"NA":6006},{"trials":5997,"activeCount":101},[],{"trials":5999,"activeCount":101},[],{"trials":6001,"activeCount":101},[],{"trials":6003,"activeCount":101},[],{"trials":6005,"activeCount":101},[],{"trials":6007,"activeCount":101},[6008],{"nctId":6009,"briefTitle":6010,"status":111,"phases":6011,"primaryCompletion":6012,"completion":6012,"start":6013,"enrollment":1630,"conditions":6014,"interventions":6015},"NCT02618343","EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron",[93],"2019-03-01","2016-10-04",[1085],[5994,6016],"Ondansetron",{"intervention":6016,"totalTrials":134,"cells":6018},{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6023,"PHASE3":6025,"PHASE4":6027,"NA":6029},{"trials":6020,"activeCount":101},[],{"trials":6022,"activeCount":101},[],{"trials":6024,"activeCount":101},[],{"trials":6026,"activeCount":101},[],{"trials":6028,"activeCount":101},[],{"trials":6030,"activeCount":101},[6031],{"nctId":6009,"briefTitle":6010,"status":111,"phases":6032,"primaryCompletion":6012,"completion":6012,"start":6013,"enrollment":1630,"conditions":6033,"interventions":6034},[93],[1085],[5994,6016]]